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A B S T R A C T
Background
Pharmacological treatments for tobacco dependence, such as nicotine replacement therapy (NRT), have been shown to be safe and ef-
fective interventions for smoking cessation. Higher levels of adherence to these medications increase the likelihood of sustained smoking
cessation, but many smokers use them at a lower dose and for less time than is optimal. It is important to determine the effectiveness
of interventions designed specifically to increase medication adherence. Such interventions may address motivation to use medication,
such as influencing beliefs about the value of taking medications, or provide support to overcome problems with maintaining adherence.
Objectives
To assess the effectiveness of interventions aiming to increase adherence to medications for smoking cessation on medication adherence
and smoking abstinence compared with a control group typically receiving standard care.
Search methods
We searched the Cochrane Tobacco Addiction Group Specialized Register, and clinical trial registries (ClinicalTrials.gov and the WHO In-
ternational Clinical Trials Registry Platform) to the 3 September 2018. We also conducted forward and backward citation searches.
Selection criteria
Randomised, cluster-randomised or quasi-randomised studies in which adults using active pharmacological treatment for smoking ces-
sation were allocated to an intervention arm where there was a principal focus on increasing adherence to medications for tobacco de-
pendence, or a control arm providing standard care. Dependent on setting, standard care may have comprised minimal support or varying
degrees of behavioural support. Included studies used a measure that allowed assessment of the degree of medication adherence.
Data collection and analysis
Two authors independently screened studies for eligibility, extracted data for included studies and assessed risk of bias. For continuous
outcome measures, we calculated effect sizes as standardised mean differences (SMDs). For dichotomous outcome measures, we calcu-
lated effect sizes as risk ratios (RRs). In meta-analyses for adherence outcomes, we combined dichotomous and continuous data using the
generic inverse variance method and reported pooled effect sizes as SMDs; for abstinence outcomes, we reported and pooled dichotomous
outcomes. We obtained pooled effect sizes with 95% confidence intervals (CIs) using random-effects models. We conducted subgroup
analyses to assess whether the primary focus of the adherence treatment ('practicalities' versus 'perceptions' versus both), the delivery
approach (participant versus clinician-centred) or the medication type were associated with effectiveness.
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Main results
We identified two new studies, giving a total of 10 studies, involving 3655 participants. The medication adherence interventions studied
were all provided in addition to standard behavioural support.They typically provided further information on the rationale for, and em-
phasised the importance of, adherence to medication or supported the development of strategies to overcome problems with maintaining
adherence (or both). Seven studies targeted adherence to NRT, two to bupropion and one to varenicline. Most studies were judged to be
at high or unclear risk of bias, with four of these studies judged at high risk of attrition or detection bias. Only one study was judged to
be at low risk of bias.
Meta-analysis of all 10 included studies (12 comparisons) provided moderate-certainty evidence that adherence interventions led to small
improvements in adherence (i.e. the mean amount of medication consumed; SMD 0.10, 95% CI 0.03 to 0.18; I2 = 6%; n = 3655), limited by
risk of bias. Subgroup analyses for the primary outcome identified no significant subgroup effects, with effect sizes for subgroups impre-
cisely estimated. However, there was a very weak indication that interventions focused on the 'practicalities' of adhering to treatment (i.e.
capabilities, resources, levels of support or skills) may be effective (SMD 0.21, 95% CI 0.03 to 0.38; I2 = 39%; n = 1752), whereas interventions
focused on treatment 'perceptions' (i.e. beliefs, cognitions, concerns and preferences; SMD 0.10, 95% CI –0.03 to 0.24; I2 = 0%; n = 839) or on
both (SMD 0.04, 95% CI –0.08 to 0.16; I2 = 0%; n = 1064), may not be effective. Participant-centred interventions may be effective (SMD 0.12,
95% CI 0.02 to 0.23; I2 = 20%; n = 2791), whereas those that are clinician-centred may not (SMD 0.09, 95% CI –0.05 to 0.23; I2 = 0%; n = 864).
Five studies assessed short-term smoking abstinence (five comparisons), while an overlapping set of five studies (seven comparisons) as-
sessed long-term smoking abstinence of six months or more. Meta-analyses resulted in low-certainty evidence that adherence interven-
tions may slightly increase short-term smoking cessation rates (RR 1.08, 95% CI 0.96 to 1.21; I2 = 0%; n = 1795) and long-term smoking
cessation rates (RR 1.16, 95% CI 0.96 to 1.40; I2 = 48%; n = 3593). In both cases, the evidence was limited by risk of bias and imprecision,
with CIs encompassing minimal harm as well as moderate benefit, and a high likelihood that further evidence will change the estimate of
the effect. There was no evidence that interventions to increase adherence to medication led to any adverse events. Studies did not report
on factors plausibly associated with increases in adherence, such as self-efficacy, understanding of and attitudes toward treatment, and
motivation and intentions to quit.
Authors' conclusions
In people who are stopping smoking and receiving behavioural support, there is moderate-certainty evidence that enhanced behavioural
support focusing on adherence to smoking cessation medications can modestly improve adherence. There is only low-certainty evidence
that this may slightly improve the likelihood of cessation in the shorter or longer-term. Interventions to increase adherence can aim to
address the practicalities of taking medication, change perceptions about medication, such as reasons to take it or concerns about doing
so, or both. However, there is currently insufficient evidence to confirm which approach is more effective. There is no evidence on whether
such interventions are effective for people who are stopping smoking without standard behavioural support.
P L A I N   L A N G U A G E   S U M M A R Y
Can we help smokers to increase their use of stop-smoking medicines?
Background
Medicines designed to make it easier for people to stop smoking, such as nicotine replacement therapy (NRT), bupropion and varenicline,
are safe and successfully help people to quit. However, people often do not follow the instructions that come with the medicines properly,
which may mean that the medicines do not work as well as they could. This probably reduces a person's chances of giving up smoking
for good. In this review, we looked at whether there are ways to help people to use stop-smoking medicines correctly, and whether this
makes people more likely to quit smoking.
Study characteristics
We searched for studies up to September 2018, and we found 10 studies, including 3655 people. All of these people were smokers, over
18 years of age. Studies tested different ways of helping people use their stop-smoking medicines properly. Typically this meant provid-
ing additional information about the medicine or helping people to overcome problems they had with taking the medicine. One study
delivered support by telephone, and the rest provided at least some face-to-face support. All included studies measured the amount that
people used their medicines and all but one measured how many people quit smoking.
Key results
People who received help to improve their use of medicines to stop smoking used their medicines slightly more than people who did not
receive this help. There was some evidence that this also led to slightly more people quitting smoking.
Quality of the evidence
The evidence that helping people improve their use of stop-smoking medicines can successfully boost the use of these medicines is of
moderate quality, meaning that more evidence could make us feel more certain of this effect. This is because there were problems with
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the methods of some of the included studies. The evidence suggesting that approaches to improve the use of stop-smoking medicines
can help more people to quit smoking is of low quality, which means that we are not confident that they do actually help more people
to quit and further evidence may or may not strengthen our confidence in this effect. This is because there were problems with some of
the study methods and because it is unclear whether providing extra support to encourage people to use their medicines leads to more
or fewer people successfully quitting smoking.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Interventions to increase adherence compared to standard care for improving adherence to
medications for tobacco dependence and abstinence from smoking
Interventions to increase adherence compared to standard care for improving adherence to medications for tobacco dependence and abstinence from smoking
Patient or population: adult smokers
Settings: typically in-person clinical settings (China, UK, USA)
Intervention: interventions to increase adherence through providing information and facilitating problem-solving
Comparison: behavioural support for smoking cessation
Illustrative comparative risks (95% CI)
Assumed risk Corresponding risk
Outcomes Relative effect (95% CI)
















Mean proportion of pre-
scribed medication con-
sumed over 28 days was
3.9% higher (95% CI
1.2% to 7.0% higher)
3655












386 people per 1000
achieve abstinence
(95% CI 343 to 432)
1795












236 per 1000 achieve ab-
stinence
(95% CI 195 to 284)
3593
(5 RCTs; 7 comparisons)
⊕⊕⊝⊝
Lowa,b,c
The basis for the illustrative comparative risks is provided in Footnotesd. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the com-
parison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio; SMD: standardised mean difference.
GRADE Working Group grades of evidence

















































































































































Moderate certainty: current evidence provides a good indication of the likely effect, and the likelihood that the actual effect of the treatment will not be substantially dif-
ferent is moderate.
Low certainty: current evidence provides some indication of the likely effect, but the likelihood that the actual effect will be substantially different is high.
Very low certainty: current evidence does not provide a reliable indication of the likely effect, and the likelihood that the actual effect will be substantially different is very
high.
aMost studies were at high or unclear risk of bias which lowers confidence in estimate of effect (risk of bias).
bWe did not downgrade due to indirectness as we judged the evidence specifically relating to the general population receiving an adherence intervention in addition to behav-
ioural support for smoking cessation, compared to behavioural support alone, is moderate. However, our conclusions cannot be generalised to populations not receiving be-
havioural support or that are unlikely to adhere, or both.
cIncluded sufficient sample size for single adequately powered trial but 95% CI overlapped no effect and ranged from minimal harm to moderate benefit (imprecision).
dConcerning adherence outcomes for the comparison group, as the basis for an illustration of potential effect size on a more familiar metric, we used data from the largest included
study that reported adherence as assessed by tablet counts (Marteau 2012). In this study, mean proportion of prescribed nicotine replacement therapy that was consumed at
28 days by the 'standard care' arm was 63.6% (SD 39.0%). Further explanation is provided in Data synthesis. Concerning abstinence outcomes for the comparison group, the
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B A C K G R O U N D
Description of the condition
Smoking  is one of the  largest preventable causes of disease and
premature death worldwide, being a key causal factor in heart dis-
ease, stroke, chronic lung disease and cancers (GBD 2018). Pharma-
cological treatments for tobacco dependence, such as nicotine re-
placement therapy (NRT), are widely considered to be safe and ef-
fective interventions for smoking cessation. One Cochrane system-
atic review found that participants using NRT were over 1.5 times
more likely to achieve abstinence than those who did not (Hart-
mann-Boyce 2018). Participants using bupropion, nortriptyline and
varenicline are also more likely to stop smoking than those using
placebo (Cahill 2016; Hughes 2014). However, studies have shown
that many smokers who use medications for tobacco dependence
do so at a lower dose and for less time than the evidence suggests is
optimal (Cheong 2010; Hays 2010; Shiffman 2008; Swan 2010). For
example, Burns and Levinson reported that users of NRT, on aver-
age, continue medication for less than half the time for which it was
prescribed (Burns 2008). Observational evidence controlling for re-
verse causation (whereby people whose quit attempt was faltering
choose not to adhere to their medication) showed that prior ad-
herence to medication promoted later abstinence (Hollands 2013;
Shiffman 2007; Shiffman 2008). One review of this relationship, al-
though highlighting the lack of high-quality studies, suggested that
the degree of adherence predicted subsequent abstinence (Rau-
pach 2014). Therefore, it is important to know whether interven-
tions aiming to increase adherence are effective and whether this
in turn improves abstinence, the evidence for which we reviewed
here.
Description of the intervention
Interventions that specifically aim to increase adherence to pre-
scribed medications vary widely in their content and characteris-
tics (Nieuwlaat 2014). Examples may include, but are not limited
to, improved or increased information provision, monitoring and
feedback concerning performance, reminders, and psychological
therapy or counselling. In the specific context of medications for to-
bacco dependence, general behavioural support for smoking ces-
sation may include components that target increasing medication
adherence. Interventions that are additional to standard behav-
ioural support and that devote special attention to improving ad-
herence may also be delivered, such as addressing individuals' be-
liefs about the value of taking medications or providing additional
support to overcome barriers to adherence.
More-specific intervention types can be characterised by reference
to two key factors informed by the Perceptions and Practicalities
Approach (PAPA) (Horne 2013). This approach proposes that non-
adherence can be both intentional and unintentional depending on
a person's motivations and capabilities. Perceptual factors ('per-
ceptions'), that is, beliefs, cognitions, concerns and preferences,
as well as practical factors ('practicalities'), that is, capabilities, re-
sources, levels of support or skills, can explain non-adherence and
be addressed by interventions to increase adherence. Current guid-
ance in England on medicines adherence emphasises both percep-
tions and practicalities for improving medication adherence (NICE
2009). PAPA emphasises the importance of tailoring intervention
content by eliciting and appreciating the needs, cognitions or be-
haviours of the patient or participant, and can, therefore, be con-
sidered 'participant-centred'. By contrast, adherence focused in-
terventions that are primarily 'clinician-centred' tend to be stan-
dardised, directive or didactic in nature. We used this approach to
categorise interventions in this review.
Why it is important to do this review
To our knowledge, no other published systematic review address-
es this question. Reviews of studies of behavioural support inter-
ventions (e.g. Hartmann-Boyce 2019; Lancaster 2017), which may
include elements that target medication adherence, are not de-
signed to disentangle the specific effects of those components that
focus on increasing adherence. Previous reviews of interventions
designed to increase adherence have focused on specific patient
groups or treatment contexts, or have not covered smoking cessa-
tion treatments (Nieuwlaat 2014). A specific review of the topic is
valuable because we cannot be certain that findings relating to ad-
herence to other medications are generalisable to smoking cessa-
tion medications, as these provide a unique treatment context with
specific issues for adherence. For example, many people see stop-
ping smoking without medication as the best way to stop smoking
(Morphett 2015). Additionally, the drawbacks of failing to adhere
are less significant than they may be in the treatment of illness. For
example, individuals may successfully quit smoking without adher-
ing to therapy, or if they fail to adhere and continue to smoke, they
may not feel that they have lost anything or experienced any ad-
verse effects. There is evidence to suggest that it may be more dif-
ficult to persuade individuals of the benefits of using smoking ces-
sation medications compared with other health conditions. Ham-
mond 2004 found that over a third of smokers reported that use
of pharmacotherapies (NRT or bupropion) would either make no
difference or actually reduce the likelihood of quitting smoking.
Smokers who perceived cessation assistance methods to be bene-
ficial were more likely to use medication in the future. Finally, some
users may perceive risks of harm to their health from the medica-
tion that outweigh the potential benefits.
O B J E C T I V E S
To assess the effectiveness of interventions aiming to increase ad-
herence to medications for smoking cessation on medication ad-
herence and smoking abstinence compared with a control group
typically receiving standard care.
To assess which intervention approaches are most effective; and
determine the impact of interventions on potential precursors of
adherence, such as understanding of the treatment and efficacy
perceptions.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised, cluster-randomised or quasi-randomised studies.
Types of participants
Adults (aged 18 years and over) smoking at point of entry into a
study.
Types of interventions
All participants across relevant intervention and comparator study
arms must have been offered effective pharmacological treatment
Interventions to increase adherence to medications for tobacco dependence (Review)
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for smoking cessation. Pharmacological treatments comprised
those prescribed to increase cessation rates (e.g. NRT, bupropion,
nortriptyline, varenicline and combination regimens).
Interventions to increase adherence may vary widely in their nature
(Nieuwlaat 2014), and so the nature of the interventions considered
for inclusion in this review were not specified beyond reference
to exclusion criteria. Eligible interventions included any interven-
tion that differed from standard care administered to smokers, and
where the differing intervention content had a clear principal focus
on increasing adherence to medications for tobacco dependence,
reflected in described content and stated aims. We did not include
interventions that systematically altered the active pharmacolog-
ical characteristics of a given medication, such as dose strength,
length of treatment or means of delivery. Interventions that includ-
ed the use of financial incentives were not eligible.
Acceptable comparison groups were those that provided standard
or usual care. Depending on setting, this could comprise of minimal
support or varying degrees of behavioural support.
Types of outcome measures
Primary outcomes
• Adherence to medication for tobacco dependence.
Studies must have used a quantitative measure of adherence. This
could be defined as a continuous measure, such as the amount of
medication consumed over a given treatment period, or as a di-
chotomous outcome, indicating whether the treatment was used
to a specific quantified degree (e.g. adherence for x number of days,
or x amount of medication consumed). This is in contrast to a binary
(i.e. any amount of medication at any time versus non-use) or cate-
gorical checklist measure, which we did not consider an appropri-
ate measure. Adherence could have been measured by electronic
measure, tablet counts by a third party or through self-report (or
combinations thereof).
Where studies reported multiple measures of adherence, we used
the most stringent available. Where studies assessed treatment pe-
riods at multiple time points, we used the longest time point. Where
available, we used primary outcome data for only those partici-
pants who continued a quit attempt and remained engaged for the
duration of a treatment programme rather than dropping out, as
opposed to using outcome data from all those randomised to re-
ceive a given intervention (i.e. intention-to-treat analysis (ITT)) (see
Dealing with missing data for further details).
Secondary outcomes
• Abstinence from smoking measured near or at a time point rel-
evant to the measure of adherence (less than six months, i.e.
short-term abstinence).
Where there were data from multiple time points, we reported data
measured near or at a time point closest to the measure of adher-
ence, expected to be less than six months. Where studies reported
multiple definitions of abstinence, we used the most stringent.
• Abstinence at six months or longer (i.e. long-term abstinence)
We reported abstinence at the longest available time point of six
months or longer, in order to assess the long-term benefit of the
intervention on cessation rates. For both abstinence outcomes, we
used data as randomised (ITT), assuming people not followed up
to be smoking.
Other outcomes
• Factors plausibly associated with increases in adherence, such
as, but not limited to:
• intention or motivation to quit smoking (as measured by the
studies, likely using a self-reported questionnaire measure);
• attitudes towards treatment, or understanding of the treat-
ment (as measured by the studies, likely using a self-reported
questionnaire measure);
• self-efficacy (as measured by the studies, likely using a self-
reported questionnaire measure).
• Adverse events.
Any adverse events or harms reported in included trials, including
clinical levels of depression or anxiety.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Tobacco Addiction Group Specialized
Register on the 3 September 2018, and two trial registries (Clinical-
Trials.gov and the World Health Organization (WHO) International
Clinical Trials Registry Platform (apps.who.int/trialsearch/)).
The most recent issues of the databases included in the Register, as
searched for the current update of this review, were:
• Cochrane Central Register of Controlled trials (CENTRAL), issue
8, 2018;
• MEDLINE (via Ovid) to update 28 August 2018;
• Embase (via Ovid) to week 36 2018;
• PsycINFO (via Ovid) to update 20 August 2018.
The search strategy for the Register is given in Appendix 1. For de-
tails of the searches used to create the Specialized Register see the
Cochrane Tobacco Addiction Group's website.
Searching other resources
We conducted forwards and backwards citation searches from in-
cluded studies.
Data collection and analysis
Selection of studies
Two review authors independently screened all search results (ti-
tles and abstracts) for possible inclusion, and those selected by ei-
ther or both review authors were subjected to full-text assessment.
Two review authors independently assessed the selected full-text
articles for inclusion. Any discrepancies were resolved by consen-
sus, overseen by a third review author acting as arbiter as neces-
sary. We listed excluded studies after full-text assessment and gave
reasons for exclusion in the Characteristics of excluded studies ta-
ble.
Data extraction and management
We developed a data extraction form, which was piloted and
amended as necessary. We extracted the following main sets of da-
ta from each included study:
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• lead author;
• date;
• study participant inclusion criteria;
• participants (participant condition(s) and demographics: race/
ethnicity, gender, religion/culture, socioeconomic status, age);
• study design and timetable; randomisation; allocation conceal-
ment;
• interventions (content and format of interventions, including
details of information provided; intervention setting and deliv-
ery provider; delivery of any cointerventions, theoretical basis
of intervention if stated; intervention type coded by reference
to two factors: 1. focus on perceptions, practicalities, or both; 2.
participant-centred or clinician-centred);
• numbers of participants in each trial arm;
• outcome measures; time(s) at which outcomes assessed;
• results;
• balance of baseline characteristics;
• analysis;
• additional comments;
• study funding and authors' declarations of interest
Two review authors independently extracted data. A third review
author checked data extraction and resolved any errors or inconsis-
tencies. The first review author entered the data into Review Man-
ager 5, with another review author checking the accuracy of the da-
ta entry (Review Manager 2014).
Assessment of risk of bias in included studies
We assessed and reported the risk of bias of included studies by
outcome, in accordance with the guidelines in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). We re-
ported on the following individual domains:
• random sequence generation (selection bias);
• allocation concealment (selection bias);
• blinding of outcome assessment (detection bias) (assessed for
each main outcome or class of outcome). We did not assess risk
of performance bias pertaining to blinding of participants and
personnel due to the difficulty of achieving that in this context,
in line with the guidance of the Cochrane Tobacco Addiction
Group. It would be impractical to blind those delivering the in-
tervention and attempts to do so could introduce additional lim-
itations, such as reducing potency of the intervention by impair-
ing its delivery and introducing further systematic differences
between the intervention exposures by group;
• incomplete outcome data (attrition bias) (assessed for each
main outcome or class of outcome);
• selective reporting (reporting bias);
• other sources of bias (consistency in intervention delivery, i.e.
was the information standardised/structured; was fidelity to
protocol monitored).
Two review authors independently assessed risk of bias of included
studies, with any disagreements resolved by discussion and con-
sensus, and with a third review author acting as arbiter as neces-
sary. We present our assessment in Risk of Bias tables for each in-
cluded study.
A summary risk of bias judgement was derived for each study by
applying an algorithm suggested in Section 8.7 (Table 8.7a) of the
Cochrane Handbook for Systematic Reviews of Interventions (Hig-
gins 2011). Specifically, if the judgement in at least one of these do-
mains was 'high risk of bias' then summary risk of bias was deter-
mined to be high. If there were no judgements of 'high' risk, but the
judgement in at least one domain was 'unclear risk of bias', then the
summary risk of bias was determined to be unclear. Summary risk
of bias was only judged 'low' if judgements in all domains were 'low
risk of bias'.
Measures of treatment e:ect
For continuous outcomes where the precise nature of the mea-
sures used differed but the outcomes were regarded as compara-
ble, they were integrated and standardised to have common effect
sizes, defined as the standardised mean difference (SMD). The ef-
fect measure for comparable dichotomous outcomes was risk ratio
(RR). When different studies reported either dichotomous or con-
tinuous data for the same outcome, we combined these data us-
ing the generic inverse variance method and reported summary ef-
fect sizes as SMDs. This followed methods outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Sections 7.7.7
and 9.4.6; Higgins 2011), whereby standard errors were comput-
ed for each study by converting CIs for log odds ratios and SMDs.
Log odds ratios were converted to SMDs by multiplying each by
the required constant. Where studies provided both dichotomous
and continuous measures for the same outcome, a continuous out-
come measure was selected. Finally, we accounted for studies that
contributed multiple comparisons to the meta-analysis by reduc-
ing their sample sizes in direct relation to how often corresponding
data were used.
We obtained a pooled effect size with 95% confidence intervals (CI)
using a random-effects model.
Unit of analysis issues
We included no cluster-randomised trials and observed no unit of
analysis errors. Should we have identified any cluster-randomised
trials, where an analysis was reported accounting for the clustered
study design, we would have estimated the effect on this basis. If
that had not been possible and the information was not available
from authors, then an 'approximately correct' analysis would have
been carried out according to current guidelines (Higgins 2011). We
would have imputed estimates of the intracluster correlation (ICC)
using estimates derived from similar studies or by using general
recommendations from empirical research. If it was not possible to
implement these procedures, we would have given the effect esti-
mate as presented but reported the unit of analysis error.
Dealing with missing data
In the context of smoking cessation medications, it would be in-
formative for measures of adherence to include only those partic-
ipants who continue a quit attempt and not all those allocated to
receive a given intervention (Hollands 2013). Including those peo-
ple who abandon a quit attempt is less appropriate because first,
treatment such as NRT is not indicated when a person has ceased
trying to quit smoking, and second, it potentially confounds adher-
ence with initial uptake (which may be influenced by different fac-
tors). As such, we are most interested in adherence to medication
in those individuals who continue to engage with a treatment pro-
gramme and do not dropout from the intervention, and hence re-
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main in the study. Therefore, we intended to analyse data for our
primary outcome in this way where available. In practice, prima-
ry outcomes for included studies were often presented as ITT, with
five instances where it was clear that adherence was assessed and
reported only for those who remained engaged with treatment or
at least with study follow-up (Mooney 2005; Nollen 2011; Schlam
2018; Smith 2013; Tucker 2017). For secondary smoking cessation
outcomes, we assumed that people not followed up had resumed
smoking following Cochrane Tobacco Addiction Group guidance.
For such abstinence outcomes, ITT data were reported in all cases.
Assessment of heterogeneity
We tested for heterogeneity by inspecting the overlap of CIs and
quantified this using the I2 statistic (which describes the percent-
age of the variability in effect estimates due to heterogeneity rather
than sampling error). We considered a value greater than 50% to
represent substantial heterogeneity (Higgins 2011).
Assessment of reporting biases
We assessed likelihood of publication bias using funnel plots for the
primary adherence outcome as there were at least ten studies with-
in that analysis (Sterne 2011).
Data synthesis
We conducted a narrative synthesis of the included studies, pre-
senting studies' major characteristics and results. As studies were
sufficiently similar in terms of setting, population, interventions
and outcomes (including the time(s) at which these are assessed),
we pooled the data statistically. We used a random-effects model
for meta-analysis to obtain a pooled effect size with 95% CIs, due
to observed clinical heterogeneity in study characteristics, such as
differences in the treatment contexts and outcome measures used.
Certainty of the evidence
We used the GRADE framework to rate the certainty of each body of
evidence relating to an outcome that was incorporated into a meta-
analysis, to indicate the confidence that may be placed in summary
estimates of effect (Guyatt 2011). This is an assessment of the like-
lihood that the true effect will not be substantially different from
what the research found. Within the GRADE approach, the certainty
of a body of evidence for intervention effects is assessed based on
the design of the underlying studies, with randomised controlled
trials (RCTs) initially considered high certainty, and on a number
of factors that can decrease or increase certainty. GRADE criteria
for downgrading certainty of evidence encompass risk of bias, in-
consistency, imprecision, indirectness, publication bias and oth-
er considerations. If such a criterion is identified, it is classified ei-
ther as serious (leading to downgrading by one level) or very seri-
ous (downgrading by two levels). The four possible certainty ratings
that can be applied are:
• high certainty (meaning that current evidence provides a very
good indication of the likely effect, and the likelihood that the
actual effect will be substantially different is low);
• moderate certainty (current evidence provides a good indica-
tion of the likely effect, and the likelihood that the actual effect
of the treatment will not be substantially different is moderate);
• low certainty (current evidence provides some indication of the
likely effect, but the likelihood that the actual effect will be sub-
stantially different is high); and
• very low certainty (current evidence does not provide a reliable
indication of the likely effect, and the likelihood that the actual
effect will be substantially different is very high).
'Summary of findings' tables
The 'Summary of findings' table comprises summaries of the es-
timated intervention effect and the number of participants and
studies for each main outcome, and includes justifications under-
pinning GRADE assessments. In this case, we completed a 'Sum-
mary of findings' table for the primary adherence outcome and
the secondary abstinence outcomes: short-term abstinence and
long-term abstinence. Results of meta-analyses are presented as
SMDs and RRs, with 95% CIs. To facilitate interpretation of effect
sizes for the primary outcome that were expressed as SMDs, we
re-expressed these in a more familiar metric (similar to the ap-
proach used in other Cochrane Reviews (e.g. Crockett 2018; Hol-
lands 2015a). Because, to our knowledge, there is no larger more
definitive survey that uses objective measurement of levels of ad-
herence within standard care, for this translation we used outcome
data from Marteau 2012. This was the largest study included with-
in the current review that, first, reported adherence at least part-
ly assessed by tablet counts, and second, used a general popula-
tion sample in primary care (meaning that its data on adherence is
likely to be relatively generalisable). Specifically, we used the stan-
dard deviation of the adherence outcome (here assessed as propor-
tion of prescribed NRT that was consumed at 28 days) within the
control group (here being the phenotype arm) as this best reflects
typical adherence to medication in the absence of an intervention
(i.e. within standard care). Such translations have important lim-
itations and are only intended to be broadly illustrative to guide
interpretation of the pooled result from the meta-analysis. For ex-
ample, what is considered 'standard care' inevitably differs, and in
this study involved communicating to smokers that they were be-
ing prescribed a higher or lower dose based on their level of nico-
tine dependence. In addition, NRT may not be representative of all
medications used to treat tobacco dependence. More generally, re-
expressed values relate directly to data derived from only one sam-
ple with its own context and measurement characteristics and so
applying them more widely inevitably extrapolates beyond this.
Subgroup analysis and investigation of heterogeneity
We used subgroup analyses for the primary outcome to exam-
ine the specific characteristics or components of adherence inter-
ventions that may explain their effectiveness, an understanding
of which could inform the design of maximally effective interven-
tions. We coded more specific intervention types using the PAPA
approach (Horne 2013). First, we coded whether interventions fo-
cused on perceptual factors ('Perceptions'; i.e. beliefs, cognitions,
concerns and preferences) or practical factors ('Practicalities'; i.e.
capabilities, resources, levels of support or skills), or both. Second,
we coded whether the intervention content was shaped by elic-
iting and appreciating the needs, cognitions or behaviours of the
patient or participant ('Participant-centred') or was primarily stan-
dardised, directive or didactic in nature ('Clinician-centred'). We
also looked at these two factors in combination. Finally, we con-
ducted a subgroup analysis looking at differential effects on adher-
ence by the type of prescribed medication, although seven of the
10 studies focused on NRT medication.
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Sensitivity analysis
We conducted a sensitivity analysis for the primary and secondary
outcome analyses, removing the studies at high risk of bias.
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies; and Characteristics of
studies awaiting classification tables for additional details of stud-
ies. Table 1 provides a brief overview of the nature of adherence in-
terventions used in the included studies.
Results of the search
The searches for this update retrieved 294 unique records. 10 ar-
ticles were identified as potentially eligible for inclusion after title
and abstract screening. Of these, six articles were excluded at the
full-text screening stage. Of the remaining four records, one was
classified as an ongoing study (NCT02635919), and three contained
information on two new studies eligible for inclusion in the review
(Schlam 2018; Tucker 2017). The flow of studies through the sys-
tematic review process for this update is shown in Figure 1.
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Figure 1.   Study flow diagram for the current review update (eight studies were included in the previous version of
the review).
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Figure 1.   (Continued)
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Included studies
The review included 10 studies (eight previously included in Hol-
lands 2015b), and two new at this update. These 10 studies includ-
ed 3655 randomised participants (Chan 2010; Chan 2011; Marteau
2012; Mooney 2005; Mooney 2007; Nollen 2011; Schlam 2018; Sch-
mitz 2005; Smith 2013; Tucker 2017).
Types of studies
All trials were individually randomised controlled trials. Five trials
involved randomisation into two groups which were both included
in our analysis (Marteau 2012; Mooney 2007; Nollen 2011; Schmitz
2005; Tucker 2017), and three trials involved randomisation into
three groups, where only two of these groups were eligible for this
review (Chan 2010; Chan 2011; Mooney 2005). One trial involved a
2 × 2 × 2 factorial design with eight randomised groups, but these
groups were collapsed into a two-group comparison, relevant to
this review, by the study authors (Smith 2013). One trial involved a
2 × 2 × 2 × 2 × 2 factorial design with 32 randomised groups, with
these groups collapsed into three two-group comparisons relevant
to this review (Schlam 2018).
Types of participants and settings
Eight studies included a general population of smokers. Two stud-
ies included only participants with a specific clinical condition,
namely erectile dysfunction (Chan 2010) and HIV/AIDS (Tucker
2017). The mean ages of participants in trials ranged from 34.6 years
(Mooney 2005) to 49 years (Schmitz 2005). In two trials, all partic-
ipants were women (Mooney 2007; Schmitz 2005). In one trial, all
participants were men (Chan 2010). In the remaining trials, per-
centage women ranged from 7.5% (Tucker 2017) to 62.5% (Nollen
2011). Seven trials took place in the USA (Mooney 2005; Mooney
2007; Nollen 2011; Schlam 2018; Schmitz 2005; Smith 2013; Tucker
2017), two in Hong Kong, China (Chan 2010; Chan 2011), and one
in the UK (Marteau 2012). Regarding setting, all but one of the in-
cluded studies featured interventions that were at least in part de-
livered in-person, with the other delivering the intervention by tele-
phone (Smith 2013). The interventions were delivered in clinic (e.g.
smoking cessation or outpatient clinics) or social service settings,
apart from one that was delivered by telephone (Smith 2013), one
where one of the three adherence interventions was delivered by
automated telephone call (Schlam 2018), and two where the set-
ting was unclear (Chan 2010; Chan 2011). Those delivering the inter-
vention were trained counsellors or project staH (Chan 2010; Chan
2011; Mooney 2005; Nollen 2011; Schlam 2018; Smith 2013; Tuck-
er 2017), nurses (Marteau 2012; Schmitz 2005), or cognitive behav-
ioural therapy (CBT) practitioners (Mooney 2007).
Types of interventions
The trials all offered pharmacological treatment and some behav-
ioural support, comprising a form of smoking cessation counselling
with no particular emphasis on adherence (e.g. providing dosing
instructions and weekly checks of adverse effects; Schmitz 2005),
to participants in the control arm. Support for the control arm
varied from a single support session of 16 minutes (Tucker 2017)
or 20 minutes (Mooney 2005) to seven weekly sessions (Marteau
2012; Mooney 2007; Schmitz 2005). In the main, the intervention
consisted of an additional component to the standard behaviour-
al support, with eight studies providing additional contact time for
those in the intervention arm (Chan 2010; Chan 2011; Mooney 2007;
Nollen 2011; Schlam 2018; Schmitz 2005; Smith 2013; Tucker 2017).
In the other two studies, the nature of the contact changed but its
duration did not significantly differ (Marteau 2012; Mooney 2005).
The interventions typically provided information on the rationale
for, and emphasised the importance of, adherence to medication,
and aided participants in developing strategies to overcome prob-
lems and barriers to maintaining adherence. As such, they included
a combination of two intervention strategies outlined within a tax-
onomy of interventions to increase adherence (Haynes 2008), that
is included in Appendix 2, namely 1. instruction for participants on
medication use or 2. counselling about smoking, and the value of
medication in overcoming addiction. Two studies included inter-
ventions that involved personalised feedback of medication taking,
monitored electronically (Mooney 2007; Schmitz 2005); one study
elicited participants' beliefs about medication taking and then pro-
vided personalised counselling relating to those beliefs (Mooney
2005); one study tailored medication dose to either genotype or de-
gree of tobacco dependence and explained the rationale for this
to participants (Marteau 2012); and five studies added addition-
al counselling contact time to standard behavioural support, with
content focusing on medication adherence, including the use of
motivational interviewing techniques and the 4/5R approach to in-
creasing motivation (counselling addressing risks, rewards, road-
blocks, and repetition, and relevance in the case of the 5Rs; Chan
2010; Chan 2011), a focus on motivation to use the medication
and behavioural skills for achieving this (Nollen 2011; Tucker 2017),
and targeting medication beliefs with monitoring and feedback on
adherence (Smith 2013). One study examined multiple adherence
interventions concerning personalised feedback of adherence be-
haviour, automated medication reminder calls and additional be-
havioural support content focused on adherence (Schlam 2018).
Seven studies prescribed NRT (Chan 2010; Chan 2011; Marteau
2012; Mooney 2005; Schlam 2018; Smith 2013; Tucker 2017), two
studies prescribed bupropion (Mooney 2007; Schmitz 2005), and
one study prescribed varenicline (Nollen 2011).
We categorised the content of each intervention by reference to
PAPA. Of 12 comparisons included in the review, three compar-
isons assessed the impact of changing perceptions (Marteau 2012;
Mooney 2005; Schlam 2018 (medication adherence counselling in-
tervention)), and five comparisons assessed the impact of inter-
ventions aiming to improve the practicalities of medication-tak-
ing (Chan 2010; Chan 2011; Mooney 2007; Schlam 2018 (electron-
ic monitoring feedback intervention); Schmitz 2005). Four com-
parisons assessed Interventions of perceptions and practicalities
(Nollen 2011; Schlam 2018 (automated calls intervention); Smith
2013; Tucker 2017).
We also assessed whether interventions aimed at changing per-
ceptions or practicalities assessed participants' particular beliefs
or difficulties (patient-centred) or provided a standardised inter-
vention (clinician-centred). Nine comparisons were patient-cen-
tred (Chan 2010; Chan 2011; Mooney 2005; Mooney 2007; Sch-
lam 2018 (medication adherence counselling intervention); Sch-
lam 2018 (electronic monitoring feedback intervention); Schmitz
2005; Smith 2013; Tucker 2017), and three comparisons were clini-
cian-centred (Marteau 2012; Nollen 2011; Schlam 2018 (automated
calls intervention)).
Types of outcome measures
Measures of adherence varied across studies. Five studies report-
ed at least one continuous outcome, measured as the percentage
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or amount of prescribed medication that was consumed (Marteau
2012; Mooney 2005; Nollen 2011), number of days on which it was
used (Smith 2013), or percentage of days on which a person was ad-
herent (Schlam 2018). Five studies used a dichotomous outcome,
meaning people were classified as either achieving or not achiev-
ing a specified degree of adherence that was deemed adequate
(Chan 2010; Chan 2011; Mooney 2007; Schmitz 2005; Tucker 2017).
The definitions of adequate adherence naturally varied by med-
ication type and because there may not be agreed standards for
what constitutes desirable levels of adherence. Furthermore, the
operationalisation of this was not always clear. In assessing ad-
herence, seven studies at least partly used tablet counts (Marteau
2012; Mooney 2005; Nollen 2011; Tucker 2017), or electronic mon-
itoring systems (Mooney 2007; Schlam 2018; Schmitz 2005). One
study used self-report (Smith 2013), while the means of assessing
adherence was unclear in two studies (Chan 2010; Chan 2011). The
period for which the primary adherence outcome was being as-
sessed ranged from approximately two weeks (Mooney 2005; Smith
2013), to three months (Nollen 2011).
To assess abstinence seven studies used biochemically validated
outcomes (Chan 2010; Chan 2011; Marteau 2012; Mooney 2005;
Mooney 2007; Nollen 2011; Tucker 2017), but only six of these pro-
vided useable data in study reports (Chan 2010; Chan 2011; Marteau
2012; Mooney 2005; Nollen 2011; Tucker 2017). Two studies provid-
ed self-reported abstinence data (Schlam 2018; Smith 2013), and
one study did not report abstinence (Schmitz 2005). Time of ab-
stinence outcome measurement ranged from two weeks (Mooney
2005), to six months (Chan 2010; Chan 2011; Marteau 2012; Schlam
2018; Smith 2013), to one year (Schlam 2018).
Excluded studies
We excluded six additional studies at this update. Two did not in-
clude an eligible adherence outcome (ISRCTN33423896; McClure
2013), and four did not include an eligible intervention (Cropsey
2017; Gong 2016; McClure 2016; Tseng 2017). Tseng 2017 was previ-
ously included in this review as an ongoing study; however, based
on information in the published report it was deemed ineligible
for inclusion at this update. The detailed description of the inter-
vention made it clear that the content was equally split between
standard smoking cessation support and content focused specifi-
cally on increasing medication adherence ("Each day participants
in the two TM [text message] arms received one adherence-focused
message and one IMB [information-motivation-behavioural skills
model] smoking cessation-themed message"). As one of the inclu-
sion criteria for this review stated that differing intervention con-
tent should have a clear principal focus on increasing adherence to
medications for tobacco dependence, reflected in both described
content and stated aims, we decided that this study did not meet
the eligibility criteria and would not allow us to assess the effect of
the adherence intervention independently.
We excluded 21 studies in the previous version of this review (Hol-
lands 2015b). Our previous searches also identified two studies
awaiting classification, which we were still unable to fully assess
and include due to a lack of information (Applegate 2007; Yuhongx-
ia 2011). See Characteristics of studies awaiting classification table.
Risk of bias in included studies
It is clear from the risk of bias summary that the included stud-
ies were often difficult to assess for bias on our criteria because
there was insufficient information in published reports (Figure 2).
For summary risk of bias judgements, as described in Assessment
of risk of bias in included studies, we were able to judge that
these conferred a low summary risk of bias for one study (Marteau
2012). Four studies were assessed at high risk of bias (Mooney 2005;
Mooney 2007; Schmitz 2005; Smith 2013), with the remaining stud-
ies assessed at unclear risk of bias. Few judgements were made sug-
gesting a high risk of bias for any domain, with the only four exam-
ples being risk of bias due to blinding of outcome assessment for
Smith 2013 and due to incomplete outcome data for Mooney 2005,
Mooney 2007, and Schmitz 2005.
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 2.   (Continued)
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Allocation
Three studies were at low risk of selection bias with details being
provided of an adequate sequence generation process and steps
to ensure allocation concealment (Chan 2011; Marteau 2012; Sch-
lam 2018). One study provided details of adequate allocation con-
cealment but not sequence generation (Nollen 2011), while one
study provided details of adequate sequence generation but not
allocation concealment (Smith 2013). In the other studies, there
was insufficient detail to judge the risk of selection bias (Chan 2010;
Mooney 2005; Mooney 2007; Schmitz 2005; Tucker 2017).
Blinding
We did not assess performance bias, as described in the Assess-
ment of risk of bias in included studies section. We did assess
whether outcomes were assessed blind to allocation (detection
bias). Six studies were judged to be at low risk of detection bias
(Marteau 2012; Mooney 2005; Mooney 2007; Nollen 2011; Schmitz
2005; Tucker 2017), one was judged at high risk of detection bias, as
it used self-report to assess all components of the primary adher-
ence outcome (Smith 2013), and three were judged at unclear risk
of bias (Chan 2010; Chan 2011; Schlam 2018). Some studies clearly
attempted to blind outcome assessors to the secondary abstinence
outcome (Chan 2010; Marteau 2012), although only in one study to
the primary adherence outcome (Chan 2011). Elsewhere, attempts
to blind outcome assessors were unclear (Mooney 2005; Mooney
2007; Nollen 2011; Schlam 2018; Schmitz 2005; Smith 2013; Tucker
2017). However, the use of objective outcome measures of adher-
ence and biochemical validation of abstinence (for all other than
Schlam 2018 and Smith 2013), was evidence that these outcomes
were unlikely to be affected by detection bias.
Incomplete outcome data
We deemed five studies at low risk of bias because they had low
levels of attrition, or addressed substantial or differential (or both)
attrition (Chan 2010; Chan 2011; Marteau 2012; Schlam 2018; Smith
2013). Two studies were judged to be at unclear risk of bias (Nollen
2011; Tucker 2017). Three studies were judged to be at high risk of
bias because participant numbers were not fully reported, the over-
all number of participants lost was 50% or greater, the difference
in percentage followed up between groups was 20% or more, or a
combination of these (Mooney 2005; Mooney 2007; Schmitz 2005).
Selective reporting
Four trials were preregistered on a clinical trials register enabling
us to corroborate that specified outcomes remained consistent and
so we assessed risk of bias as low (Chan 2010; Chan 2011; Marteau
2012; Smith 2013). One of these also published a protocol (Marteau
2012). A further study was preregistered on a clinical trials register
but the adherence outcomes were not specified (Schlam 2018) and
so we assessed risk of bias as unclear. We were unable to find reg-
istrations for the other five studies so selective reporting within the
final reports could not reasonably be ruled out and risk of bias was
considered unclear (Mooney 2005; Mooney 2007; Nollen 2011; Sch-
mitz 2005; Tucker 2017).
Other potential sources of bias
We regarded another potential source of bias that was relevant to
this review to be consistency in intervention delivery, judging this
by whether it was clear that the information given to participants
was standardised or structured to some degree, and fidelity to pro-
tocol was systematically monitored. Six studies were judged to be
at low risk of other bias (Chan 2011; Marteau 2012; Mooney 2005;
Nollen 2011; Schlam 2018; Tucker 2017), with the remaining four
assessed at unclear risk of bias (Chan 2010; Mooney 2007; Schmitz
2005; Smith 2013).
E:ects of interventions
See: Summary of findings for the main comparison Interventions
to increase adherence compared to standard care for improving
adherence to medications for tobacco dependence and abstinence
from smoking
Primary outcome
Adherence to medication for tobacco dependence
Five studies reported dichotomous adherence measures (Chan
2010; Chan 2011; Mooney 2007; Schmitz 2005; Tucker 2017). Chan
2010 and Chan 2011 assessed whether or not there had been
continuous use of NRT, for four weeks (Chan 2010) and eight
weeks (Chan 2011). Mooney 2007 and Schmitz 2005 both assessed
whether or not participants had taken two daily doses of bupro-
pion as prescribed over the seven-week treatment period. Tucker
2017 assessed whether participants had used six or more nicotine
patches per week, for those participants who provided complete
data at baseline and follow-up. Five studies used continuous adher-
ence measures (Marteau 2012; Mooney 2005; Nollen 2011; Schlam
2018; Smith 2013). Marteau 2012 assessed the proportion of pre-
scribed NRT consumed over the four-week treatment period and
reported the group mean. Mooney 2005 reported the mean pieces
of nicotine gum used during the first 15 days of a quit attempt in
those who completed the treatment period only. Nollen 2011 as-
sessed the proportion of prescribed varenicline doses taken over
three months, for those who remained engaged. Schlam 2018 mea-
sured the percentage of days in the first six weeks of the quit at-
tempt where participants were adherent (i.e. where participants
used both a nicotine patch and four or more pieces of gum), in those
participants who completed the treatment phase. Smith 2013 as-
sessed self-reported number of days of nicotine patch use in the
first two weeks, for those remaining engaged.
Pooled analysis of these data, comprising 12 comparisons from 10
studies, showed that adherence interventions produced a small
improvement in adherence, with no significant statistical hetero-
geneity being observed (SMD 0.10, 95% CI 0.03 to 0.18; I2 = 6%; n =
3655; Figure 3). Re-expressing this effect size produced by the pri-
mary random-effects meta-analysis in a more familiar metric (see
Data synthesis) suggested that interventions to increase adherence
could have an effect equivalent to a 3.9% increase (95% CI 1.2% to
7.0%) in the mean proportion of prescribed medications consumed
over 28 days.
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Figure 3.   Forest plot of comparison: 1 Medication adherence intervention plus standard care versus standard care
alone, outcome: 1.1 Adherence (combined dichotomous and continuous).
 
GRADE assessment indicated that the evidence for this outcome
was of moderate certainty, meaning that the true effect is probably
close to the estimated effect. This judgement was reached through
consideration of the following criteria. The current evidence was
downgraded once due to risk of bias, because the majority of stud-
ies were judged to be at high or unclear risk of bias. We did not
downgrade the evidence further based on other GRADE considera-
tions. For imprecision, the number of participants (sample size) in-
corporated into this meta-analysis exceeded the optimal informa-
tion size (i.e. a sufficient sample size for a single adequately pow-
ered trial), and the 95% CI ranged from a very small to a small bene-
fit. For inconsistency, there was minimal heterogeneity and consid-
erable overlapping of CIs. There was no clear reason to downgrade
certainty of evidence for indirectness (providing it was emphasised
that moderate evidence related only to those receiving an adher-
ence intervention in addition to behavioural support for smoking
cessation, compared to behavioural support alone). Finally, for oth-
er considerations, including publication bias, the certainty of the
evidence was not downgraded. Although a funnel plot of the prima-
ry outcome data suggested possible asymmetry (Figure 4), only one
of 12 included comparisons was statistically significant, and there
was not a clearly consistent pattern of smaller studies resulting in
greater intervention effect estimates than larger studies. This lim-
ited the plausibility of publication bias as an explanation for asym-
metry (Sterne 2011).
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Figure 4.   Funnel plot of comparison: 1 Medication adherence intervention plus standard care versus standard care
alone, outcome: 1.1 Adherence (combined dichotomous and continuous).
 
Subgroup analyses
We conducted three subgroup analyses of the primary analysis
in order to examine the relative impact of specific intervention
types in terms of their focus on 'perceptions'; 'practicalities'; or
'both' (Analysis 1.2); and whether the intervention was partici-
pant-centred or clinician-centred (Analysis 1.3). The third analysis
considered these two factors in combination (Analysis 1.4).
There was no strong evidence that the effect of interventions that
focused on perceptions, practicalities, or on both differed in their
effect on adherence (I2 = 13%, P = 0.32; Analysis 1.2). That said, the
effect of interventions focused on practicalities appeared slightly
larger than the other two groups, with an SMD of 0.21 (95% CI 0.03
to 0.38; I2 = 39%; n = 1752), compared with perceptions (SMD 0.10,
95% CI –0.03 to 0.24; I2 = 0%; n = 839), or a combination of both per-
ceptions and practicalities (SMD 0.04, 95% CI –0.08 to 0.16; I2 = 0%;
n = 1064).
There was no clear evidence that participant-centred interventions
differed in effectiveness from clinician-centred interventions (I2 =
0%, P = 0.71; Analysis 1.3). The SMD for participant-centred inter-
ventions was 0.12 (95% CI 0.02 to 0.23; I2 = 20%; n = 2791) and for
clinician-centred interventions was 0.09 (95% CI –0.05 to 0.23; I2 =
0%; n = 864).
There was also no strong evidence that combining these two clas-
sification systems led to subgroup differences in the effect of inter-
ventions on medication adherence (I2 = 0%, P = 0.65; Analysis 1.4).
We conducted a further subgroup analysis to examine whether
there were differential effects of the intervention depending on
which medication was prescribed (Analysis 1.5). In this analysis,
there was stronger evidence of subgroup differences (I2 = 68%, P =
0.04). The effect of interventions to increase adherence to bupropi-
on (SMD 0.58, 95% CI 0.14 to 1.01; I2 = 0%; n = 152) was much larger
than that for NRT (SMD 0.09, 95% CI 0.02 to 0.17; I2 = 0%; n = 3442)
or varenicline (SMD from only one study was –0.22, 95% CI –0.73 to
0.29; n = 61).
Secondary outcomes
We reported assessments measured at the time point that most
closely accorded with the assessment of adherence. If this selected
abstinence measure assessed short-term abstinence (less than six
months), we additionally report abstinence at the longest available
time point of six months or longer in order to assess the long-term
benefit of the intervention on cessation rates.
Short-term abstinence (less than six months)
Five studies contributed data to the analysis of short-term ab-
stinence (Marteau 2012; Mooney 2005; Nollen 2011; Smith 2013;
Tucker 2017). Marteau 2012 assessed biochemically validated pro-
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longed abstinence at 28 days, Mooney 2005 assessed biochemical-
ly validated point-prevalent abstinence at two weeks and Nollen
2011 assessed biochemically validated point-prevalent abstinence
at three months. Smith 2013 measured self-reported 30-day point-
prevalent abstinence at six weeks, while Tucker 2017 assessed bio-
chemically validated continuous abstinence over 90 days.
Random-effects meta-analysis pooling these data produced an RR
of 1.08 (95% CI 0.96 to 1.21; I2 = 0%; n = 1795; Analysis 1.8). This sug-
gested a potential small effect of adherence interventions on short-
term abstinence from smoking but with considerable uncertainty
due to CIs overlapping no effect and including the possibility of a
very small negative effect on abstinence.
GRADE assessment indicated that the evidence for this outcome
was of low certainty, meaning that the true effect might be marked-
ly different from the estimated effect. This judgement was reached
through consideration of the following criteria. The current evi-
dence was downgraded by one level due to risk of bias, because
the majority of studies were judged to be at high or unclear risk of
bias. It was also downgraded by one level due to imprecision, be-
cause while the number of participants (sample size) incorporated
into this meta-analysis exceeded the optimal information size (i.e.
a sufficient sample size for a single adequately powered trial), the
95% CI overlapped no effect and ranged from a very small harm to a
small benefit. We did not downgrade further due to other consider-
ations, namely inconsistency (because there was negligible hetero-
geneity), indirectness or publication bias (with insufficient studies
for formal assessment).
Long-term abstinence (six months or longer)
Five studies (seven comparisons) contributed data to long-term ab-
stinence (Chan 2010; Chan 2011; Marteau 2012; Schlam 2018; Smith
2013). All five studies assessed abstinence at six months, which was
biochemically validated in three studies (Chan 2010; Chan 2011;
Marteau 2012), and based on self-report in two studies (Schlam
2018; Smith 2013). Random-effects meta-analysis pooling these da-
ta produced an RR of 1.16 (95% CI 0.96 to 1.40; I2 = 48%; n = 3593;
Analysis 1.9). This suggested a potential small effect of adherence
interventions on long-term abstinence; however, considerable un-
certainty arose due to the lower CI including the possibility of a
very small negative effect on abstinence. Participants subject to
interventions to improve adherence were between 4% less likely
and 16% more likely to be abstinent at six months than those given
standard behavioural support.
GRADE assessment indicated that the evidence for this outcome
was of low certainty, meaning that the true effect might be marked-
ly different from the estimated effect. This judgement was reached
through consideration of the following criteria. The current evi-
dence was downgraded by one level due to risk of bias because the
majority of studies were at high or unclear risk of bias. It was also
downgraded by one level for imprecision, because while the num-
ber of participants (sample size) incorporated into this meta-analy-
sis exceeded the optimal information size (i.e. a sufficient sample
size for a single adequately powered trial), the 95% CI overlapped
no effect and ranged from a very small harm to a small benefit. We
did not downgrade further for other considerations, namely incon-
sistency (because heterogeneity was not classed as substantial), in-
directness or publication bias (there were insufficient studies for
formal assessment).
Sensitivity analyses
In sensitivity analyses, we excluded those studies at high risk of bias
to determine if the primary and secondary outcome analyses were
affected. Removing the two studies at high risk of bias (Mooney
2005; Smith 2013) did not affect results and interpretation for ei-
ther the primary outcome (adherence to medication for tobacco
dependence: SMD 0.12, 95% CI 0.02 to 0.22) or secondary outcomes
(short-term abstinence: RR 1.05, 95% CI 0.83 to 1.33; long-term ab-
stinence: RR 1.23, 95% CI 0.99 to 1.54).
Other outcomes
Factors plausibly associated with increases in adherence
No studies reported any relevant outcomes (i.e. factors plausibly
associated with increases in adherence, such as intention or moti-
vation, or attitudes towards treatment).
Adverse events
Four studies explicitly reported adverse events (Marteau 2012;
Mooney 2005; Schlam 2018; Smith 2013). In Marteau 2012, there
were no adverse events that were plausibly related to the inter-
vention or its effect on participants' exposure to medication. There
were also no differences between groups in levels of anxiety at ei-
ther one-week or six-month assessment times. In Mooney 2005,
there was no difference in adverse events between groups and in
Schlam 2018 and Smith 2013 there were no serious adverse events
during the study.
D I S C U S S I O N
Summary of main results
There is evidence of moderate certainty that interventions that de-
vote special attention to improving adherence to smoking cessa-
tion medications can improve this to a small degree, when added
to behavioural support for smoking cessation. Such interventions
involve addressing the practicalities of taking medication, includ-
ing facilitating problem solving, or providing information to ad-
dress perceptions about the value of taking medication or concerns
about doing so. There is low-certainty evidence that such interven-
tions may slightly improve the likelihood of achieving abstinence.
The evidence for these findings was limited in both quality and
quantity – characterised by a small number of studies, clinical het-
erogeneity, impaired study quality and imprecise estimates of ef-
fect, incorporating both potential benefit and harm.
Concerning the small improvement seen in adherence, translat-
ing the small statistical effect size into a more familiar metric sug-
gests a potential effect equivalent to a 4% increase in the mean
proportion of prescribed medication consumed (although see Data
synthesis for limitations of such translations). One estimate is that
each additional milligram per day of NRT consumed could increase
the odds of abstinence by 5% (Hollands 2013), so this would repre-
sent a small but appreciable increase, equivalent to consuming one
extra milligram of NRT with a prescription for 25 mg. Given evidence
that greater adherence improves cessation outcomes for people
using NRT, and evidence that higher doses of varenicline are more
effective than lower doses (Cahill 2016), it stands to reason that this
would apply to other medications too, because medication cannot
work if it is not consumed. Characteristics of the treatment could
also be shaped to attempt to increase the overall background levels
of adherence. For example, characteristics of the medication (Hol-
Interventions to increase adherence to medications for tobacco dependence (Review)









Cochrane Database of Systematic Reviews
lands 2013), and its delivery (Hajek 1999), have been shown to im-
pact on adherence. Even if adherence interventions demonstrate
effect sizes of the small magnitudes seen here, the potential for ag-
gregate impact is substantial given the extent to which medications
for tobacco dependence are currently used, at least in high-income
countries. The degree to which this ultimately applies globally is
dependent on increasing the uptake of effective pharmacothera-
pies, in part via increasing their availability and reducing their cost
(van den Brand 2017).
Given that these interventions typically involve relatively minor ad-
ditions to standard behavioural support, much of the content of
the included interventions appeared relatively homogeneous. A
detailed assessment of the content specifically concerning adher-
ence did, however, reveal some potential avenues for further inves-
tigation. Those interventions that focus on addressing the practi-
cal barriers to adherence (as opposed to perceptions of treatment)
and respond to participants' needs (as opposed to being governed
by a set clinical agenda), and those that combine both of these fo-
ci, may be the most effective. However, the evidence suggesting
this is very weak, particularly as there was no strong evidence of
subgroup differences, and hence should be treated with caution.
These tentative findings accord with English guidance on medica-
tion adherence (NICE 2009), which itself is based on a review of lit-
erature about effective interventions in adherence. This guidance
emphasises that practical factors and barriers need to be consid-
ered key to explaining non-adherence, not solely participants' be-
liefs and preferences about treatment. Furthermore, they reflect
evidence suggesting that simply providing information to target
cognitions and motivate changes in behaviour is often insufficient
without also addressing factors, such as practical actions to over-
come structural barriers, that prevent good intentions being re-
alised (Hollands 2012; Webb 2006). It is also possible that a more de-
tailed examination of intervention content would provide clearer
insight into effective and ineffective mechanisms. Deriving a more
precise understanding of the composition and processes of effec-
tive interventions will require a greater depth of evidence, includ-
ing interventions that assess mediators, and improvements in the
science and reporting of behavioural interventions (Sumner 2018).
Overall completeness and applicability of evidence
The review included only 10 trials, which were variable in terms
of their context, the components of the intervention and the mea-
sures of the primary outcome, medication adherence, which makes
summarising the data more difficult and reduces the certainty of
the estimates produced. All these studies featured participants
who were motivated to quit or reduce smoking, had sought and
were receiving some degree of behavioural support – either face-
to-face or by telephone – to take medication and were not pay-
ing for that medication. Furthermore, no studies targeted partici-
pants who were more likely to be non-adherent, such as those who
had not adhered to medication previously. Consequently, perhaps,
medication adherence was overall reasonably high. For example,
Nollen 2011 and Marteau 2012 reported the mean percentage of
prescribed doses taken in the intervention arm was over 82% and
control arm was over 63%, even though in the latter study, partic-
ipants who had given up their quit attempt and ceased follow-up
were counted as non-adherent. In studies using dichotomous mea-
sures of adequate adherence, three studies reported over 50% of
participants achieving satisfactory levels of adherence (Chan 2011;
Mooney 2007; Schmitz 2005). Perhaps in the context of the general
population of people seeking support to quit, medication use is rel-
atively high – contrary to perceptions that adherence is commonly
suboptimal – and interventions have only limited potential to en-
hance adherence further. However, most people who stop smok-
ing with the aid of medication do so without behavioural support
(Fidler 2011), and typically any medication must be purchased at
considerable cost. It is likely that adherence in this context is much
lower and that interventions to improve adherence may be partic-
ularly helpful, but also that delivering these interventions will be
especially challenging. There is currently no evidence on what may
be effective in such unsupported contexts, though it seems likely
that targeting perceptions or practicalities or both are likely to be
relevant. A final point is that there is moderate-certainty evidence
that reimbursing the costs of medication where it is not freely pro-
vided improves adherence (van den Brand 2017).
Quality of the evidence
Most studies were judged at unclear risk of bias due to poor re-
porting of randomisation, even though all of them were published
since first publication of the CONSORT statement (Moher 2010). On-
ly three studies reported procedures clearly enough to be classi-
fied as having a low risk of bias (Chan 2011; Marteau 2012; Sch-
lam 2018). It is possible, but relatively unlikely, that this led to bias.
In the context of smoking cessation clinics, trial participants are
usually unknown to the therapists, and this likely decreases, but
does not eliminate, the likelihood of therapists assigning particular
participants to particular arms and subverting the randomisation.
Nonetheless, this should be addressed in reports from future trials.
One potential source of bias is that practitioners who provided the
adherence intervention also collected data on the degree to which
people were adhering. As such they were unblinded, which may al-
so motivate participants to report better adherence. This concern
was mitigated substantially by the use of 'tablet counts', common
to most of these trials. It is encouraging that the use of more objec-
tive measures appears commonplace in these types of trials, mean-
ing that measurement issues were for the majority of studies not
considered to confer particular risk of bias. This contrasts with an-
other Cochrane Review focusing on adherence to prescription med-
ications, where most studies used self-report measures (Nieuwlaat
2014). Furthermore, while in the past, electronic monitoring ap-
proaches have been applied primarily to the opening and closing
of tablet bottles, making them suitable for certain types of medica-
tions only, technology has been developed that will enable this to
be used for other types of medication storage.
We assessed the certainty of the evidence for each outcome using
the GRADE system. For the primary adherence outcome, GRADE as-
sessment indicated that the evidence for this outcome was of mod-
erate certainty, meaning that the true effect is probably close to the
estimated effect. The current evidence was downgraded only once,
due to risk of bias, because the majority of studies were judged to
be at high or unclear risk of bias. We did not downgrade the evi-
dence further based on other GRADE considerations. Evidence was
of low certainty for both secondary outcomes of short- and long-
term abstinence, meaning that the true effect might be marked-
ly different from the estimated effect. The current evidence was
downgraded twice for each of these outcomes, in both cases being
first, for risk of bias, because the majority of studies were judged
to be at high or unclear risk of bias, and second, for imprecision,
because the 95% CI overlapped no effect and ranged from a very
small harm to a small benefit. This suggests that further research
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on abstinence outcomes will be valuable in increasing the reliabil-
ity and precision of effect estimates and the certainty we can place
in them.
Potential biases in the review process
Key possible limitations of the review are that first, we may have
failed to identify all relevant research for inclusion in the review.
We did take steps to minimise this possibility, including searching
the Tobacco Addiction Group's specialised register in addition to
electronic database searches, but this remains possible. Second, it
is possible that there was publication bias, given there was asym-
metry in the funnel plot, but we did not consider publication bias a
likely explanation (see Effects of interventions). Unfortunately, two
studies were classified as 'awaiting classification' as there was in-
sufficient available information to confirm inclusion, and we were
unable to contact the authors (Applegate 2007; Yuhongxia 2011).
Agreements and disagreements with other studies or
reviews
We are not aware of other reviews addressing this topic. Cochrane
Reviews show that behavioural support increases smoking cessa-
tion and, typically, included studies included people using medica-
tion, and receiving adherence advice as part of standard smoking
cessation support (Hartmann-Boyce 2019; Lancaster 2017). Howev-
er, the studies did not randomise people to receive or not receive
a medication adherence component so they do not provide specif-
ic evidence on its effect. Nieuwlaat 2014 examined the effect of in-
terventions to improve adherence to a wider range of medication
in a general setting. They found that information and counselling
approaches improved adherence and patient outcomes but were
unable to identify key components of the interventions. Nieuwlaat
2014 excluded tobacco dependence medications, hence the neces-
sity of this current review.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
• In people who are stopping smoking and receiving behavioural
support, there is moderate evidence that enhanced behaviour-
al support focusing on adherence to smoking cessation medica-
tion can modestly improve medication adherence, but less cer-
tainty that this may slightly increase abstinence in the short or
longer term. The additional support could be brief and focus on
reasons to take medication or concerns about doing so or the
practicalities of taking it, or both, but there is currently insuffi-
cient evidence to confirm which approach is more effective.
• There is no evidence on whether interventions to increase med-
ication adherence are effective for people who are stopping
smoking without behavioural support, and these findings may
not generalise to populations and settings where low adherence
is likely.
Implications for research
• More high-quality randomised controlled trials investigating the
effects of smoking cessation medication adherence interven-
tions on both adherence and smoking cessation are needed to
allow us to reliably estimate and interpret effects. The specific
active components of interventions that may increase medica-
tion use also remain to be delineated, requiring more systemat-
ic research but also more detailed and consistent reporting by
researchers.
• Trials should be conducted in settings and populations where
medication adherence is likely to be low because it appears that,
in the context of people quitting with medication in a behav-
ioural support programme, medication adherence is relatively
good. As such, future studies might investigate interventions to
increase medication adherence in population subgroups who
exhibit lower adherence and who may benefit more from an ad-
herence intervention, such as people who are quitting without
behavioural support, who purchase their own cessation medica-
tion, who have failed to adhere in the past or women who smoke
during pregnancy (Coleman 2012; Fish 2009).
• Investigations of remotely delivered interventions could capi-
talise on technological solutions for prompting, monitoring and
feeding back adherence behaviours in real-time, incorporating
sensor technology and digital communications and apps, as
with behavioural support for cessation (Naughton 2017).
• Research should consider supplementing interventions with
changes to proximal environmental cues that shape our behav-
iour (Hollands 2017), such as how medication is stored, present-
ed, packaged or labelled.
• Future syntheses would benefit if researchers were able to de-
fine a common outcome metric for measuring adherence. Fol-
lowing recommendations elsewhere (Hollands 2013), first, a dis-
tinction should be made between overall consumption and ad-
herence to a prescribed regimen and, because a prescribed reg-
imen may not be optimal, the former should be privileged (with
both reported preferably). Second, the actual degree of adher-
ence is usually more meaningfully assessed by continuous out-
come measures – such as milligrams of medication consumed –
and we would encourage future use where possible. This is be-
cause there is unlikely to be clear guidance as to what should
be regarded as an adequate or effective level of adherence to a
given medication, meaning dichotomous measures concerning
a specified level of adherence may be subject to greater varia-
tion and arbitrariness, and may be less directly comparable and
interpretable.
• Outcomes should be objectively assessed as far as is possible,
and as well as reporting intention-to-treat data for the entire
randomised sample, data should also be reported for the sub-
set of participants who are continuing a quit attempt at the time
of assessment, because cessation medication is not indicated
when a person has given up a quit attempt.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Design: RCT
Country: Hong Kong, China
Recruitment methods: mass media publicity and referrals from hospitals/clinics and physicians
Setting: no information other than a non-clinical setting
Participants Inclusion criteria: Chinese men; aged ≥ 18 years; self-reported erectile dysfunction; smoked ≥ 1 ciga-
rette per day; intended to quit smoking within 7 days of first contact; willing to use NRT; not following
any other smoking cessation regimen
Exclusion criteria: psychologically or physically unable to communicate; taking regular psychotropic
medications; serious health problems preventing use of NRT
Participants randomised: 501 participants in eligible groups (mean age 48.8 years (SD 11.5); 100% Chi-
nese)
Interventions Aim of intervention: to increase adherence to NRT and smoking cessation
Intervention: additional counselling component focused on medication adherence, delivered by
trained male counsellor. Patient-centred approach, utilising motivational interviewing techniques and
the 4R approach. The NRT adherence intervention was developed from WHO guidelines on adherence
interventions which emphasise the importance of adhering to the prescribed dosage, assessed and dis-
cussed ways to overcome barriers, and delivered problem-oriented interventions to improve adher-
ence.
Participants received 15 minutes of face-to-face smoking cessation counselling and 3 minutes of NRT
adherence counselling, plus 1 week of free NRT (gum or patch) at first contact. They were tested for CO
and given a self-help quitting pamphlet. They also received a telephone hotline number of a counsel-
lor. There was further counselling and CO testing at 1 week and 4 weeks, plus 1 week of NRT at 1 week.
At 1 week, NRT usage was checked and additional adherence counselling was given. At 4 weeks NRT us-
age was checked and additional counselling given as needed.
Control: same content apart from the NRT adherence counselling at baseline and the NRT checking and
adherence counselling at week 1.
Chan 2010 
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Outcomes Primary adherence outcome (dichotomous data): continuous use of NRT for 4 weeks, assessed at 3
months (ITT data). Checked by self-report via telephone contact and possibly tablet counts of medica-
tion also used, although procedure unclear.
Other adherence outcomes: 8-week NRT adherence rate at 3 months. Checked by telephone call at 3
months. This outcome related to adherence beyond the treatment period with no NRT being supplied.
Secondary outcomes: self-reported 7-day point prevalent abstinence, assessed at 6 months; Biochem-
ically validated quit rate, assessed at 6 months (selected as abstinence outcome by review authors);
self-reported reduction (≥ 50%) in cigarette consumption, assessed at 6 months.
Notes An additional 218 participants were randomised to a third arm (B) which was ineligible for this review:
"Group B received a 10-minute face-to-face counseling session, with simple advice to quit smoking".
Abstinence outcome not reported by arm and so not useable data in report. Study authors were con-
tacted and supplied data in April 2014, confirming that the biochemically validated quit rate for the in-
tervention group (A1) was 13.3% (33/249) and for the control group (A2) was 9.5% (24/252).
The study was funded by the Research Grants Council, Hong Kong. Nicotine patches/gums were provid-
ed free of charge from Pfızer. No conflicts of interest were reported.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details given to enable judgement beyond stating that it was randomised
(p. 252, paragraph 7). No evidence of systematic differences between arms,
with no reported differences in baseline demographic and smoking character-
istics (p. 253, paragraph 7).
Allocation concealment
(selection bias)
Unclear risk No details given to enable judgement.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Insufficient details of procedure to enable judgement although longer-term
follow-up by telephone was conducted by staH blinded to assignment (p. 253,
paragraph 2). Adherence outcomes may have included tablet counts of med-
ication used as well as self-report by telephone but procedure unclear (p. 253,





Low risk ITT analysis used and reported (p. 253, paragraph 7). No differences in attrition
between arms (p. 253, paragraph 8) with numbers being reported, the overall
number of participants lost being < 50% and the difference in percentage fol-
lowed up between groups being < 20%.
Selective reporting (re-
porting bias)
Low risk Trial was preregistered ISRCTN13070778 with specified outcomes remaining
consistent for the study report.
Consistency in interven-
tion delivery
Unclear risk No details given to enable judgement.
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Country: Hong Kong, China
Recruitment methods: local media publicity and by contacting previous cohorts of smokers who had
cessation counselling but failed to quit.
Setting: no information, but appeared to be smoking cessation clinic.
Participants Inclusion criteria: aged ≥ 18 years; Chinese; smoked ≥ 2 cigarettes per day; no intention to quit in the
next 4 weeks but interested in reducing smoking; not following any other smoking cessation regimen;
no contraindication to NRT
Exclusion criteria: psychologically or physically unable to communicate; taking regular psychotropic
medications; serious health problems preventing use of NRT; pregnant/intending to become pregnant
in next 6 months
Participants randomised: 928 participants in eligible groups (mean age 41.9 years (SD 10.3); 19.4%
women; 100% Chinese)
Interventions Aim of intervention: to increase adherence to NRT, and smoking reduction and cessation.
Intervention: additional counselling component focused on medication adherence, delivered by
trained smoking cessation counsellor. Patient-centred approach, utilising motivational interviewing
techniques and the 5R approach. The NRT adherence intervention was developed from WHO guidelines
on adherence interventions which emphasise the importance of adhering to the prescribed dosage, as-
sessed and discussed ways to overcome barriers, and delivered problem-oriented interventions to im-
prove adherence.
Participants received 15 minutes of face-to-face smoking reduction intervention, including information
on the health consequences of smoking and counselling emphasising achieving the goal of cessation
by focusing on reduction before quitting, highlighting how reduction is effective when quitting is diffi-
cult and how to reduce their smoking. They also received 3 minutes of NRT adherence counselling plus
1 week of free NRT (gum or patch) at first contact. They were tested for CO and given a self-help quitting
pamphlet. There was further smoking reduction and adherence counselling and CO testing at 1 week,
plus administration of a further 3 weeks of NRT. NRT usage was also checked. At 4 weeks, participants
received a similar intervention as at 1 week.
Control: same content apart from the NRT adherence counselling at baseline, week 1 and week 4.
Outcomes Primary adherence outcome (dichotomous data): continuous use of NRT over 8 weeks, assessed at 3
months (ITT data). Checked by self-report via telephone contact but possibly also by tablet counts and
procedure not clear.
Other adherence outcomes: continuous use of NRT over 4 weeks, assessed at 3 months.
Secondary outcomes: self-reported 7-day point prevalent abstinence, assessed at 6 months; biochem-
ically validated quit rate, assessed at 6 months (selected as abstinence outcome by review authors);
self-reported 7-day point prevalent abstinence, assessed at 3 months; Self-reported reduction (≥ 50%)
in cigarette consumption, assessed at 6 months.
Notes An additional 226 participants were randomised to a third arm (B) which was ineligible for this review:
"Subjects in control group B received 10 min simple advice on the health hazards of smoking and the
importance of smoking cessation".
The study was funded by the Health and Health Services Research Fund, Hong Kong SAR. Nicotine
patches/gums were provided free of charge from McNeil AB (Helsingborg, Sweden), which had no other
role in this trial. There were no conflicts of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Chan 2011  (Continued)
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Random sequence genera-
tion (selection bias)
Low risk Used random numbers generated by a computer prior to participant recruit-
ment (p. 1156, paragraph 6). No evidence of systematic differences between
arms, although reported difference between arms in baseline CO level and not
mentioned if this is adjusted for in the analysis (p. 253, paragraph 7).
Allocation concealment
(selection bias)
Low risk Allocation sequence was determined by a research assistant not conducting
the intervention. Assignment was by opening sealed, opaque envelopes and
followed informed consent (p. 1156, paragraph 6).
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Research assistants contacting participants at follow-up were blinded to arm
allocation (p. 1157, paragraph 2), but it was not clear that this was the only
means by which the primary outcome was assessed. Adherence outcome was
seemingly checked by self-report but combination of tablet counts of med-
ication used and self-report may have been used and procedure not clear (p.
1156, paragraph 6; p. 1157, paragraph 2). Abstinence outcome was biochemi-




Low risk ITT analysis used and reported with non-respondents at follow-up treated
conservatively as non-adherent and continuing smokers (p. 1158, paragraph
1). There were no differences in attrition between arms (p. 1158, paragraph 2)
with numbers being reported, the overall number of participants lost < 50%
and the difference in percentage followed up between groups < 20%.
Selective reporting (re-
porting bias)
Low risk Trial was preregistered ISRCTN05172176 with specified outcomes remaining
consistent for the study report.
Consistency in interven-
tion delivery
Low risk Some sessions conducted by each of the counsellors were recorded and vali-
dated by an experienced nurse supervisor.






Recruitment methods: participants were recruited through NHS primary care practices. Smokers were
identified through practice registers and sent a letter offering assistance to quit and an invitation to
participate in the trial.
Setting: smoking cessation clinics in primary care
Participants Inclusion criteria: smoking ≥ 10 cigarettes per day; wanting to quit smoking; aged ≥ 18 years
Exclusion criteria: none stated
Participants randomised: 633 participants (mean age 47.3 years (SD 13.3); 54.3% women; 90.2% white
Interventions Aim of intervention: to increase adherence to NRT by informing participants that their oral dose is tai-
lored based on an analysis of their genotype, rather than their phenotype (FTND score).
Intervention: communicating different means of tailoring prescribed medication, delivered by trained
research nurses. Behavioural support (based on withdrawal-orientated therapy) and nicotine patches
were provided (with the patch dose tailored in relation to cigarettes per day) to all participants. Partici-
pants were also prescribed an oral NRT product of their choice. The dose of oral NRT in the intervention
arm was tailored based on gene variant. Participants were given both forms of NRT 1-day prequit and
told the basis for their dosage. They were also provided with a personalised booklet and an appoint-
Marteau 2012 
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ment card documenting the dose of NRT to use daily and giving the reason for the dose. The rationale
for the dose was reiterated at each subsequent clinic. Behavioural support was offered twice prior to
quit day, weekly afterwards for 4 weeks and then at 8 weeks. Quit day was set 2 weeks and 1 day after
baseline. Support sessions lasted 10–30 minutes, depending on progress and stage of quit attempt.
Control: same content apart from the dose of oral NRT and the corresponding communication of the
rationale was tailored based on FTND score.
Outcomes Primary adherence outcome (continuous data): proportion of all prescribed NRT taken over 28 days,
assessed at 28 days of treatment period (ITT data). Checked by tablet counts of medication used.
Other adherence outcomes: proportion of all prescribed NRT taken over 7 days; proportion of partici-
pants showing no use of NRT; proportion of participants showing use of NRT beyond 28 days.
Secondary outcomes: biochemically validated prolonged abstinence at 28 days; biochemically validat-
ed prolonged abstinence at 6 months; anxiety assessed using the short-form Spielberger State-Trait
Anxiety Inventory-6.
Notes Phenotype arm was regarded as control arm as it is more similar to standard care.
Funded by Medical Research Council, UK. 1 author reported having completed consultancy and re-
search on smoking cessation for pharmaceutical companies. The remaining authors declared no con-
flicts of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random sequence was computer generated (p. 4, paragraph 2). No evidence
of systematic differences between arms, with no reported differences in base-
line demographic and smoking characteristics (p. 6, Table 1).
Allocation concealment
(selection bias)
Low risk Allocation was conducted from a central isolated location, separate from tri-
al co-ordination and participant recruitment (p. 4, paragraph 2). The randomi-
sation sequence was revealed sequentially and concealed from the trial team,
nurses and participants (p. 4, paragraph 3).
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Outcome assessors for primary outcome were not blinded, but because tablet
counts were used it was unlikely that this constituted a clear risk of bias. Out-
come assessors for longer-term follow-up were blinded to allocation (p. 4,
paragraph 3). Primary adherence outcome was checked by tablet counts of
medication used (p. 3, paragraph 5). Abstinence outcomes were biochemically




Low risk ITT analysis was used and reported with non-respondents at follow-up treated
conservatively as non-adherent and continuing smokers (p. 4, paragraph 11).
There were no differences in attrition between arms (p. 7, paragraph 3) with
numbers being reported, the overall number of participants lost being < 50%
and the difference in percentage followed up between groups being < 20%.
Selective reporting (re-
porting bias)
Low risk Study was preregistered including specified outcomes and these were un-




Low risk Standardised script used, detailed in the published protocol (p. 3, paragraph
3).
Summary risk of bias Low risk Summary risk of bias assessed as low.
Marteau 2012  (Continued)
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Recruitment methods: recruited from community via radio, newspaper and handbill advertisements
Setting: research clinic at tobacco research centre
Participants Inclusion criteria: aged 18–65 years; physically healthy; smoking 15–50 cigarettes per day for ≥ 1 year;
no untreated major mental illness; no contraindications for nicotine gum use; no concurrent use of oth-
er nicotine or tobacco products; experienced past nicotine withdrawal syndrome according to DSM
Exclusion criteria: pregnancy
Participants randomised: 63 participants (mean age 34.6 years (SD 10.9); 55.6% women; 87.3% white)
Interventions Aim of intervention: investigate if a brief low-cost intervention increased adherence to NRT.
Intervention: additional personalised feedback component focused on medication use/adherence, de-
livered by smoking cessation counsellors. Participants initially received a presentation on the benefits
of quitting, a review of coping skills, and support and encouragement. Personalised feedback was then
delivered that addressed the effectiveness, safety and necessity of nicotine replacement. First, facts
were presented about NRT followed by personalised feedback based on responses to 3 questionnaires
completed at visit 1 (the BMQ, the ANRT-12 and the PRNR). Tailored scripts were used to reinforce cor-
rect knowledge and promedication beliefs. In contrast, incorrect knowledge, negative or ambivalent
positions were raised using non-confrontational language that allowed for engagement, reflection and
clarification. A clarifying statement would then be offered. The broader goal was to define the pros and
cons of treatment and shiR the decisional balance toward adequate use of gum. The intervention was a
single session of approximately 20 minutes.
Control: participants received a presentation on the benefits of quitting, a review of coping skills, and
support and encouragement. A smoking history section reviewed general smoking experiences. This
section was intended as a 'placebo' topic with some face relevance, but little probable influence on
gum use.
Outcomes Primary adherence outcomes: (dichotomous data) rates of gum adherence of 12 pieces per day (for
those who received medication and started the treatment phase, not ITT); (continuous data) total gum
use (in participants completing the treatment phase, not ITT). Total gum use selected as primary out-
come as most stringent continuous measure that is more meaningful and informative than potentially
arbitrary dichotomised variable. Checked by tablet counts of medication used. Assessed for days 1–15.
Other adherence outcomes: daily gum use
Secondary outcomes: biochemically validated point-prevalent abstinence at 1 week; biochemically val-
idated point-prevalent abstinence at 2 weeks (selected by the review authors as most stringent and
consistent with adherence outcome time point); self-reported point-prevalent abstinence at 4, 5, 6 and
7 weeks; NHLBI defined abstinence at 3 and 6 weeks.
Additional secondary outcome measures for which the data are not reported were as follows: 3 mea-
sures of attitudes and knowledge about NRT at weeks 1, 6 and 7 (BMQ, ANRT-12, PRNR); The Minnesota
Nicotine Withdrawal Scale.
Adverse events relating to nicotine toxicity and nicotine gum were also assessed.
Notes An additional 34 participants were randomised to an additional "contingency management" arm not
eligible for inclusion in this review, in which participants received payment for using nicotine gum.
Funded by National Institute on Drug Abuse. GlaxoSmithKline provided the nicotine gum. No informa-
tion on conflicts of interest.
Mooney 2005 
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Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details given to enable judgement, although no evidence of systematic dif-




Unclear risk No details given to enable judgement.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Not clear that outcome assessors were blinded, but because tablet counts
were used it is unlikely that this constitutes a clear risk of bias. Primary adher-
ence outcome was checked by tablet counts of medication used (p. 569, para-





High risk There were no significant differences in attrition over time across all 3 arms
(p. 571, paragraph 4), but the 2 arms of interest had substantial and differing
(by > 20%) attrition levels over the treatment period of 31% (intervention) and
55% (control). Data reported for the primary outcome dId not refer to all ran-
domised participants and reasons for dropout were not detailed.
Selective reporting (re-
porting bias)
Unclear risk Unable to find any trial registration or published protocol.
Consistency in interven-
tion delivery
Low risk A standardised script and checklist used (p. 568 paragraph 7).






Recruitment methods: not reported
Setting: outpatient research clinic, located at a university medical centre
Participants Inclusion criteria: women; aged 20–65 years; physically healthy; smoking ≥ 10 cigarettes per day; no
current DSM-IV Axis 1 disorder
Exclusion criteria: pregnancy/breastfeeding; current treatment with bupropion or other smoking cessa-
tion medication
Participants randomised: 55 participants (mean age 42.1 years (SD 10); 100% women; 61.8% white)
Interventions Aim of intervention: to provide feedback on medication use (using electronic MEMS to increase bupro-
pion adherence.
Intervention: provision of additional feedback on adherence levels, given by a CBT therapist. Follow-
ing baseline assessment all participants began 7 weeks of open-label treatment with bupropion SR 300
mg dispensed in MEMS bottles (containing a computer chip that recorded the times when bottle open-
ing occurred). In addition, all participants received individual weekly CBT sessions for smoking cessa-
tion, focusing on identification of high-risk situation for smoking, coping skills training and lapse recov-
ery strategies. In the intervention condition the weekly CBT was increased in duration by 10 minutes
Mooney 2007 
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a session, during which time the MEMS feedback was given in graphical form and the treatment regi-
men was clarified. Problem-solving techniques were used to help the participant to tailor the regimen
to their schedule by associating medication taking with regular activities or routines. Potential barriers
to adherence identified and strategies for removing barriers discussed. Participants were encouraged
to self-monitor tablet consumption on daily diaries reviewed at the next therapy session.
Control: as above but without the extra 10 minutes added to each session for enhanced therapy.
Outcomes Primary adherence outcome (dichotomous data): rates of full adherence, i.e. 2 doses taken per day in
an optimal schedule (ITT data). Assessed daily over 7-week treatment period, objectively using MEMS
bottles.
Other adherence outcomes: rates of dose adherence, i.e. 2 doses taken per day over 7-week treatment
period.
Secondary outcomes: biochemically validated abstinence at week 6 (selected as abstinence outcome
by review authors. as most consistent with adherence outcome time point but there is no useable data
in the report); biochemically validated abstinence at week 3.
Notes Authors contacted in 2015 to request data for secondary abstinence outcome but no response re-
ceived. Funded by National Institute on Drug Abuse. GlaxoSmithKline provided the bupropion SR. No
information on conflicts of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details given to enable judgement.
Allocation concealment
(selection bias)
Unclear risk No details given to enable judgement.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Not clear that outcome assessors were blinded, but because MEMS monitoring
data used it was unlikely that this constituted a clear risk of bias. Primary ad-





High risk There were no differences in attrition between arms (p. 878, paragraph 2), but
more than 50% of participants did not complete the study. Data reported for
the primary outcome appeared to refer to all randomised participants.
Selective reporting (re-
porting bias)
Unclear risk Unable to find any trial registration or published protocol.
Consistency in interven-
tion delivery
Unclear risk No details given to enable judgement.






Recruitment methods: not detailed
Nollen 2011 
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Setting: community-based clinic serving a predominantly black population
Participants Inclusion criteria: black; aged ≥ 18 years; smoking > 10 cigarettes per day; wanting to quit; willing to
take varenicline.
Exclusion criteria: planning to move from the area within 3 months; contraindications to the use of
varenicline, including a cardiovascular event in the month prior to enrolment, renal impairment, taking
insulin for diabetes but unwilling to closely monitor blood sugar or history of clinically significant aller-
gic reactions to varenicline; a major depressive disorder in the past year requiring treatment; history of
alcohol or drug dependency in the past year; history of psychosis, panic disorder, bipolar disorder or
any eating disorders; current breastfeeding, pregnancy, or plans to get pregnant in the next 3 months.
Participants randomised: 72 participants (mean age 46.8 years (SD 11.3); 62.5% women; 100% black)
Interventions Aim of intervention: to improve varenicline use.
Intervention: standard components plus additional adherence support counselling. These were deliv-
ered by study counsellors although their disciplinary backgrounds/training were not detailed.
The standard components comprised: 1. culturally targeted quit smoking guide addressing the health
consequences of smoking, benefits of quitting and strategies to promote abstinence; 2. a 1-month
supply of varenicline in a monthly tablet box. Participants were verbally instructed on how to take the
medication. Participants were encouraged to initiate varenicline on day 1, set a quit date on day 8 and
to not smoke cigarettes during the 3-month treatment phase. Participants returned to the clinic at the
end of months 1 and 2 for medication refills; 3. standard counselling: all participants met with a study
counsellor during the randomisation visit to develop a plan for quitting on day 8. Counsellors followed
semi-structured scripts to provide information about the risks of continued smoking, benefits of quit-
ting, discuss strategies for coping with withdrawal and assist participants in developing a quit plan.
The additional adherence support counselling comprised 5 additional counselling sessions on days 8,
12, 20, 30 and 60 of the treatment period. Using the Information-Motivation-Behavioural skills model of
adherence behaviour change, counsellors provided information to enhance participants' motivation in
their ability to take the medication as prescribed (e.g. consequences of adherence/non-adherence) and
behavioural skills for managing adverse effects (e.g. nausea) and remembering to take their medication
(e.g. timing doses with daily activities).
Control: 3 standard components only.
Outcomes Primary adherence outcome (continuous data): percentage of prescribed varenicline doses taken at 3
months (for those remaining engaged to provide data). Assessed during monthly medication refill clinic
visits by research staH with tablet counts.
Other adherence outcomes: percentage of prescribed varenicline doses taken at 1 month; percentage
of prescribed varenicline doses at 2 months.
Secondary outcomes: biochemically validated 7-day PPA at 3 months, verified by salivary cotinine (se-
lected as abstinence outcome by review authors as most consistent with adherence outcome time
point); biochemically validated 7-day PPA at 1 month, verified by CO; biochemically validated 7-day
PPA at 2 months, verified by CO. Reduction in self-reported cigarettes per day from baseline, assessed
at 3 months. Adverse events assessed.
Notes Participant numbers per arm not given for primary outcome in published paper. We contacted the au-
thors for clarification and they confirmed that 29 participants for control arm and 32 for intervention
arm (August 2014).
Funded by University of Kansas Cancer Center and Pfizer Global Pharmaceuticals. Pfizer Global Phar-
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of allocation sequence not detailed, although no significant differ-
ences between arms at baseline reported.
Allocation concealment
(selection bias)
Low risk Allocation determined by drawing a sealed envelope with preassigned ran-
domisation numbers, at the randomisation visit (p. 869, paragraph 4).
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Not clear that outcome assessors were blinded, but because tablet counts
were used it was unlikely that this constituted a clear risk of bias. Primary ad-





Unclear risk The overall level of attrition was moderate across the treatment period (15–
21%), but reasons for dropout not detailed. No reported differences in attrition
by arm (p. 870, Results paragraph 1) with numbers being reported, the overall
number of participants lost being < 50% and the difference in percentage fol-
lowed up between groups being < 20%. Data reported for the primary outcome
did not appear to refer to all randomised participants.
Selective reporting (re-
porting bias)
Unclear risk Unable to find any trial registration or published protocol.
Consistency in interven-
tion delivery
Low risk Standard counselling was delivered according to semi-structured scripts. Ad-
herence counselling was delivered based on a model of adherence behaviour
change. All counselling sessions were audiotaped and integrity of protocols
was checked by weekly supervision of audiotaped sessions.






Recruitment methods: participants recruited from primary care clinics. Clinical staH invited smokers in-
terested in quitting to participate. Interested participants were called by researchers to assess eligibili-
ty.
Setting: primary care clinics in 2 healthcare systems in southern Wisconsin
Participants Inclusion criteria: aged ≥ 18 years; smoking ≥ 5 cigarettes per day for previous 6 months; motivated to
quit; read, write and speak English; agree to complete assessments; planning to remain in area for ≥ 12
months; not currently taking bupropion or varenicline; agree to use only study cessation medication
during treatment; no medical contraindications to NRT; agreeing to use approved contraception.
Exclusion criteria: none stated
Participants randomised: 544 participants (mean age 46.2 years (SD 12.8); 59.0% women; 87.4% white;
56.9% at least some college education).
Interventions Aim of intervention: to examine the effect of various interventions on smokers' adherence to combined
nicotine patch and nicotine gum during a quit attempt. Study was a 2 × 2 × 2 × 2 × 2 randomised facto-
rial experiment (i.e. 32 treatment conditions) evaluating 5 intervention components: 1. MAC vs none;
2. automated medication adherence calls vs none; 3. electronic medication monitoring with feedback
and counselling vs e-monitoring alone; 4. 26 vs 8 weeks of nicotine patch plus nicotine gum and 5.
Schlam 2018 
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maintenance counselling vs none. Interventions 1–3 were eligible interventions for the purposes of this
review.
Intervention: all participants received a base cessation treatment (8 weeks of nicotine patch plus nico-
tine gum, and a total of 50 minutes of counselling. Randomised intervention components were as fol-
lows: 1. MAC vs none: comprised 2 × 10-minute in-person counselling sessions delivered by case man-
agers that provided information tailored to correct misconceptions regarding cessation medication; 2.
automated medication adherence calls vs none: comprised 7–11 brief automated medication reminder
calls that offered information and encouragement for using medication as recommended; 3. electron-
ic medication monitoring with feedback and counselling vs e-monitoring alone: comprised being giv-
en printouts showing daily gum use (as electronically recorded by the dispenser that all participants
instructed to use) along with 5–9 10-minute counselling sessions delivered by case managers that fo-
cused on printouts and problem solving to increase adherence.
Control: all participants received a base cessation treatment (8 weeks of nicotine patch plus nicotine
gum, and a total of 50 minutes of counselling. Each of the 3 eligible interventions described above were
compared to the absence of that intervention.
Outcomes Primary adherence outcome (continuous data): combined patch and gum use (percentage of days in
first 6 weeks of the quit attempt adherent to both nicotine patch and gum, meaning where participants
used both a patch and ≥ 4 pieces of gum) for those remaining engaged to provide data (i.e. in partici-
pants completing the treatment phase, not ITT). Assessed during monthly medication refill clinic vis-
its by research staH with nicotine patch use assessed by timeline follow-back and gum use assessed via
electronic medication dispenser given to participants.
Other adherence outcomes: patch use (percentage of days participants used the patch in the first 6
weeks of the quit attempt); gum use (mean pieces of gum per day used in the first 6 weeks of the quit
attempt).
Secondary outcomes: self-reported 7-day PPA at 26 weeks in those randomised (selected as abstinence
outcome by review authors as most consistent with adherence outcome time point), assessed by par-
ticipants reporting smoking since last contact in a timeline follow-back interview; self-reported 7-day
PPA at 52 weeks.
Notes Authors contacted 7 November 2018 to obtain adherence and abstinence data in form needed. Out-
comes included in the review related to sample on which adherence analysis conducted (513 partici-
pants). Multiple comparisons from this study were entered into meta-analyses. To account for this and
ensure these data were not overweighted in the analyses, sample sizes were reduced in proportion to
how many times the study data were used for any given analysis. Comparisons used from this study for
primary and secondary analysis were as follows (in order from top to bottom of the forest plot): first =
1. MAC vs none; second = 2. automated medication adherence calls vs none; third = 3. electronic med-
ication monitoring with feedback and counselling vs e-monitoring alone. Data used were as follows for
primary analysis: MAC vs none (28.32 (SD 32.47) vs 29.30 (SD 32.71). Number reduced by one third and
rounded down (so 85 participants used), as study data entered 3 times into analysis; automated ad-
herence calls vs none (29.82 (SD 33.09) vs 27.80 (SD 32.07). Number reduced by one third and rounded
down (so 85 participants used); electronic medication monitoring counselling vs e-monitoring alone
(34.28 (SD 35.92) vs 23.27 (SD 27.77). Number reduced by one third and rounded down (so 86 and 85
participants used respectively).
Funded by grants from the National Cancer Institute to the University of Wisconsin Center for Tobacco
Research and Intervention and by the Wisconsin Partnership Program. No conflicts of interest declared.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomisation via a database that used stratified, computer-generated, per-
muted block randomisation. No evidence reported of systematic differences
between arms.
Schlam 2018  (Continued)
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Allocation concealment
(selection bias)
Low risk StaH could not view the allocation sequence and the database did not reveal
participants' treatment condition to staH until participants' eligibility was con-
firmed. Participants were blinded to treatment condition until they provided
consent.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Not clear that outcome assessors (case managers) were blinded. Medication
counts were partly used, meaning it was unlikely that this constituted a clear
risk of bias, but also unclear that risk of bias could be reasonably excluded. Pri-
mary adherence outcome was checked in part by tablet counts of medication
used assessed via electronic medication dispenser (gum use) given to partici-
pants (p. 2067, paragraph 2), but also part assessed via self-report via timeline
follow-back (patch use). Abstinence outcomes were self-report (p. 2067, para-




Low risk Participants were included in analyses if they had ≥ 14 days of both nicotine
gum and patch use data in the first 6 weeks post-target quit day (513; 94% of
the 544 randomised participants) (p. 2067, final paragraph). Attrition there-








Low risk Standard protocol used with example scripts for all counselling sessions (see
supplementary tables to Schlam 2016).






Recruitment methods: advertisements in local papers and radio announcements
Setting: outpatient research clinic, located at a university medical centre
Participants Inclusion criteria: English-speaking; women; aged 30–70 years; physically healthy; smoking ≥ 10 ciga-
rettes per day
Exclusion criteria: dependence on other substances; evidence of psychotic, depressive or anxiety disor-
ders; pregnancy/breastfeeding; serious medical problems
Participants randomised: 97 participants (mean age 49 years (SD 9.9); 100% women; 72% white)
Interventions Aim of intervention: to determine whether tablet taking instructions and personalised feedback using
MEMS enhanced bupropion adherence.
Intervention: provision of additional feedback on adherence levels, given by a clinic nurse. Participants
received written and verbal instructions on proper administration of bupropion. All doses were admin-
istered in MEMS bottles (containing a computer chip that recorded the times when bottle opening oc-
curred) in the morning and 1 in the evening with at least 8 hours (but not more than 12 hour) between.
Participants in the intervention group were told about the recording device in the bottle cap, specifical-
ly that the cap would record the time and date that they took the medication. MEMS feedback was giv-
en in graphical form weekly with repeated instructions to increase adherence and a check of adverse
effects. Feedback sessions lasted approximately 5–10 minutes. Treatment regimen 7 weeks in duration
with weekly counselling visits.
Schmitz 2005 
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Control: no particular information, direction or feedback beyond the standard dosing instructions. Par-
ticipants met briefly with nurse for a weekly check of adverse effects. The control arm was designed to
typify usual care in a medical setting.
Outcomes Primary adherence outcome (dichotomous data): rates of full adherence i.e. 2 doses taken per day in
an optimal schedule (ITT data). Assessed daily over 7-week treatment period, objectively using MEMS
bottles.
Other adherence outcomes: rates of dose adherence i.e. 2 doses taken per day over 7-week treatment
period.
Secondary outcomes: none reported
Notes Funded by National Institute on Drug Abuse and the Department of Psychiatry at the University of
Texas – Houston. No information on conflicts of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details given to enable judgement. No reported systematic differences




Unclear risk No details given to enable judgement.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Not clear that outcome assessors were blinded, but because MEMS monitoring
data used it was unlikely that this constituted a clear risk of bias. Primary ad-





High risk There were no differences in attrition between arms (p. 142, paragraph 7), but
> 50% of participants did not complete the study. We assumed that data re-
ported refers to all randomised participants (given wording used and consis-
tent with reported degrees of freedom for F-tests).
Selective reporting (re-
porting bias)
Unclear risk Unable to find any trial registration or published protocol.
Consistency in interven-
tion delivery
Unclear risk No details given to enable judgement.




Methods Design: RCT. 2 × 2 × 2 factorial design examining 3 manipulations, only 1 of which was relevant to this
review.
Country: USA
Recruitment methods: people who called the Wisconsin Tobacco Quit Line (WTQL) were invited to par-
ticipate in the study. There was no additional advertising or targeted recruitment.
Setting: counselling intervention conducted by telephone
Smith 2013 
Interventions to increase adherence to medications for tobacco dependence (Review)









Cochrane Database of Systematic Reviews
Participants Inclusion criteria: aged ≥ 18 years; English speaking; smoking ≥ 10 cigarettes/day; willing to set a quit
date within the next 30 days
Exclusion criteria: pregnant or lactating; medical contraindications for study medications (e.g. past 30
days, myocardial infarction or stroke; past 6 months, serious or worsening angina, very rapid or irregu-
lar heartbeat requiring medication); unwillingness to use study medications
Participants randomised: 987 participants (mean age 41.9 years (SD 13.0); 57.6% women; 76.4% white)
Interventions Aim of intervention: to address problematic beliefs or knowledge about NRT that might adversely af-
fect appropriate use of the pharmacotherapies.
Intervention: all participants received a standard quit guide in the mail, access to recorded medica-
tion information (via telephone), and access to an online cessation programme maintained by the quit-
line. They could make ad hoc calls to the quitline for additional assistance. They received standard ces-
sation counselling. During call 1, quitline counsellors discussed smoking history, prior quit attempts,
problem-solving and coping strategies, social support, and appropriate use of cessation medications;
also, a target quit date was set during this first call. Call 2 occurred on or close to the quit date and fo-
cused on management of withdrawal symptoms, appropriate use of medications, strategies to main-
tain abstinence in high-risk situations and early relapse prevention. Calls 3 and 4 addressed relapse
prevention but counselling was tailored to address concerns and questions raised by the participant.
In addition, intervention participants received MAC during all standard counselling calls. The MAC pro-
tocol was developed by study investigators and involved the following: 1. prequit assessment of beliefs
that might undermine NRT adherence, 2. ongoing medication adherence assessment by counsellors
and 3. tailored coaching based on the ongoing assessments.
Control: standard quit materials and standard counselling only.
Outcomes Primary adherence outcome (continuous data): self-reported number of days of nicotine patch use in
the first 2 weeks in those remaining engaged at this time point (this was the most relevant outcome giv-
en the factorial design because all participants irrespective of randomised arm received nicotine patch-
es for ≥ 2 weeks).
Other adherence outcomes: self-reported number of days of gum use in the first 2 weeks; self-reported
number of weeks of nicotine patch use in the first 6 weeks; self-reported number of weeks of gum use
in the first 6 weeks.
Secondary outcomes: 30-day PPA at 6 weeks postquit (selected as time point most relevant to adher-
ence outcome), 30-day PPA at 12 weeks postquit, 30-day PPA at 26 weeks postquit (selected as longest
time point). 7-day PPA at 2 weeks postquit; 7-day PPA at 6 weeks postquit; 7-day PPA at 12 weeks
postquit; 7-day PPA at 26 weeks postquit. Abstinence outcomes were assessed by self-report.
Notes The study used a factorial design to examine the effect of 3 different enhancements to quitline treat-
ment: 1. patch only vs combination (patch plus oral) NRT; 2. shorter vs longer duration of NRT; 3. stan-
dard counselling vs counselling to increase NRT adherence. We are only interested in the effect of the
latter, with data for this comparison collapsing the other factor conditions.
Study authors contacted and responded August 2014 in seeking exact number of participants by arm
for primary outcome. Their response indicated that there were 386 participants in the standard coun-
selling group and 413 participants in the adherence counselling group.
Study funded by a National Cancer Institute grant. 3/10 authors reported no financial conflicts of inter-
est with other authors declaring interests.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Participants were randomly assigned to the 8 treatment combinations via a list
of randomised numbers generated by SAS Proc Plan (SAS Institute Inc., Cary,
Smith 2013  (Continued)
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NC) (p. 719). No evidence of systematic differences between arms, with no re-




Unclear risk Insufficient details to determine that allocation was adequately concealed.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Outcome data were collected by university-based research staH not affiliated
with the quitline, but it was unclear if they were blinded (p. 720, paragraph 5).
Primary adherence outcome was only measured by self-report via telephone,




Low risk The level of attrition was moderate (18–20%) and not different between arms
(p. 721, paragraph 5) and reasons for dropout were given. Numbers were re-
ported, the overall number of participants lost was < 50% and the difference in
percentage followed up between groups was < 20%. Not ITT (p. 720, Analysis
plan and statistical methods paragraph 1).
Selective reporting (re-
porting bias)
Low risk Study was preregistered including specified primary outcomes and these were
unchanged in study report (NCT01087905).
Consistency in interven-
tion delivery
Unclear risk No details given to enable judgement although seemed to (if not clearly stat-
ed) follow a basic protocol in terms of outlining the intended focus of each
call.






Recruitment methods: study was advertised at health clinics and social service agencies serving peo-
ple with HIV in the study area, magazines targeting the lesbian, homosexual, bisexual and transgender
Latino community, and social networking sites geared toward homosexual and bisexual men.
Setting: single in-person session at a social service agency
Participants Inclusion criteria: aged ≥ 18 years; self-identified as both Latino and HIV-positive; smoked ≥ 20 days and
5 cigarettes per day in last month; ready to set a quit date within next 30 days (score 7 on the Readiness
to Quit Ladder); willing to use the nicotine patch
Exclusion criteria: self-reporting any medical condition preventing use of nicotine patch; currently us-
ing other tobacco products or e-cigarettes; currently in another smoking cessation treatment; partici-
pated in the formative phase of the project
Participants randomised: 40 participants (mean age 42.9 years (SD: standard care 8.1; adherence 9.4);
7.5% women; 0% white)
Interventions Aim of intervention: brief adherence-focused intervention module designed specifically to increase ad-
herence with the nicotine patch.
Intervention: adherence treatment followed the same basic structure as the standard treatment, but
included an additional module on improving adherence to patch use. The module was designed to help
smokers build motivation to use the patch (e.g. by weighing the pros and cons of patch use through a
decisional balance exercise), establish realistic expectations about the patch (e.g. by understanding
the extent to which withdrawal symptoms and urges will be reduced and how long it would take), de-
Tucker 2017 
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velop personalised strategies to remember to use the patch (e.g. by linking patch application to daily
routine like brushing teeth), and deal with temptations to not use the patch (e.g. by identifying person-
al triggers for not using the patch and devising a plan for avoiding or dealing with these triggers). Con-
tact time was 27 minutes in the adherence group. Single in-person session.
Control: standard brief smoking cessation treatment (followed the 5 As protocol (Ask, Advise, Assess,
Assist, Arrange and nicotine patch).
All participants received an 8-week supply of nicotine patches and a pamphlet on quitting smoking.
Contact time in the standard group was 16 minutes. Single in-person session.
Outcomes Primary adherence outcome (dichotomous data): participants were classified as adherent with the
nicotine patch if they used ≥ 6 patches per week. Assessed using self-report of number of days of patch
use between baseline and follow-up (8 weeks) and by asking participants to return at follow-up all of
the patches they had been given and conducting a count of their used patches. Outcome was for com-
plete case sample (i.e. participants who had complete data at baseline and follow-up/participants
completing the treatment phase, not ITT).
Other adherence outcomes: none
Secondary outcomes: 7-day PPA and 90-day continuous abstinence (i.e. time since quit day), verified
via breath CO monitoring (≤ 5 ppm). 90-day continuous abstinence (assessed at 90 days) was selected
as the outcome most relevant to adherence outcome, using ITT data for all randomised.
Notes 22/34 follow-up participants returned their patches; the remaining 12 participants provided only self-
reports of number of patches used.
Study funded by National Institute on Drug Abuse. No information on conflicts of interest.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details given to enable judgement. No evidence of systematic differences
between arms, although participants in the adherence intervention condition
reported significantly greater last year quit attempts (treated as a covariate in
the analyses) (p. 151, paragraph 1).
Allocation concealment
(selection bias)
Unclear risk No details given to enable judgement.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Not clear that outcome assessors were blinded, but because used patch
counts were used for majority of participants completing treatment, consid-
ered unlikely to constitute a clear risk of bias. Primary adherence outcome
was assessed by objective patch counts of medication used where possible
and this was the case for majority of participants (22/34) with self-report data
where tablet counts not available (1234) (p. 150, paragraph 5). Abstinence out-




Unclear risk Attrition across both groups was 15% (calculated from information on p. 150),
but numbers not reported by group and with no information as to whether
there was differential dropout although study had small absolute numbers of
participants (p. 151, Results).
Selective reporting (re-
porting bias)
Unclear risk Unable to find any trial registration or published protocol.
Consistency in interven-
tion delivery
Low risk Intervention was a module with structure.
Tucker 2017  (Continued)
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Quote: "Sessions were audio-recorded, with 30% of sessions reviewed by the
second or third author to ensure intervention fidelity" (p. 150, paragraph 2).
Summary risk of bias Unclear risk Summary risk of bias assessed as unclear.
Tucker 2017  (Continued)
4R: Risks, Rewards, Roadblocks, and Repetition; 5R: Relevance, Risks, Rewards, Roadblocks, and Repetition; ANRT-12: Attitudes about
Nicotine Replacement Therapy questionnaire; BMQ: Beliefs about Medicines Questionnaire; CBT: cognitive behavioural therapy; CO: car-
bon monoxide; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; FTND: Fagerstrom Test for Nicotine Depen-
dence; NHLBI: National Heart, Lung, and Blood Institute; ITT: intention to treat; MAC: medication adherence counselling; MEMS: Medication
Event Monitoring Systems; NHS: National Health Service; NRT: nicotine replacement therapy; PPA: point-prevalence abstinence; PRNR:
Perceived Risks of Nicotine Replacement questionnaire; RCT: randomised controlled trial; SD: standard deviation; WHO: World Health Or-
ganization.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Aveyard 2007 Intervention not principally focused on increasing adherence to medications for tobacco depen-
dence – the protocol for the behavioural support interventions "did not specify the nature of the
support offered". Adherence outcome was of use/not of use for specific time periods – assessing
"whether NRT was being used in general and not the degree of adherence".
Bansal-Travers 2010 Intervention not principally focused on increasing adherence to medications for tobacco depen-
dence. Both intervention and control included a focus on medication use.
Berlin 2011 Intervention not principally focused on increasing adherence to medications for tobacco depen-
dence – it was not suggested that this was an aim for the study or that the intervention was being
employed to encourage increased adherence in participants.
Bock 2014 Intervention not principally focused on increasing adherence to medications for tobacco depen-
dence.
Brendryen 2008 Intervention not principally focused on increasing adherence to medications for tobacco depen-
dence. Participants in both the intervention and control arms "recommended the use of NRT and
contained information about such products and their use".
Buchanan 2004 Intervention not principally focused on increasing adherence to medications for tobacco depen-
dence. Both intervention and control included a focus on medication use and for the intervention
arm the component focused on medication use was 1 of multiple elements relating to smoking ces-
sation.
Cropsey 2017 Intervention not principally focused on increasing adherence to medications for tobacco depen-
dence.
Gariti 2009 Intervention not principally focused on increasing adherence to medications for tobacco depen-
dence. Both intervention and control included a focus on medication use.
Gong 2016 Intervention not principally focused on increasing adherence to medications for tobacco depen-
dence.
ICRFGPRG 1993 Intervention not principally focused on increasing adherence to medications for tobacco depen-
dence.
Ingersoll 2009 Intervention not principally focused on increasing adherence to medications for tobacco depen-
dence. Intervention and control conditions were 2 different formats both "designed to provide mo-
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Study Reason for exclusion
tivation for cessation and patch use through attention to the participants' own assessment of their
reasons to quit, tools needed to quit, and goal-setting around quitting or reducing smoking".
ISRCTN33423896 No eligible adherence outcome assessed.
Lando 1988 Intervention not principally focused on increasing adherence to medications for tobacco depen-
dence. For the intervention materials the adherence component was 1 of multiple elements – "em-
phasis was placed upon a range of behavioral coping mechanisms of which gum was simply one
major strategy for combating urges to smoke".
Lifrak 1997 Intervention not principally focused on increasing adherence to medications for tobacco depen-
dence. Both intervention and control included a focus on medication use.
McClure 2013 No eligible adherence outcome assessed.
McClure 2016 Intervention not principally focused on increasing adherence to medications for tobacco depen-
dence.
Okuyemi 2006 Intervention not principally focused on increasing adherence to medications for tobacco depen-
dence. Both intervention and control included a focus on medication use.
Okuyemi 2013 Intervention not principally focused on increasing adherence to medications for tobacco depen-
dence. Intervention was seemingly focused on both smoking cessation and adherence compo-
nents with smoking cessation being the primary outcome.
Raupach 2010 Not an eligible study design – historical cohort study.
Rigotti 2013 Intervention not principally focused on increasing adherence to medications for tobacco depen-
dence. Intervention was focused on both smoking cessation and adherence components with
smoking cessation being the focus of the stated aim and the stated primary outcome.
Shaughnessy 1987 No eligible adherence outcome assessed.
Shiffman 2000 Intervention not principally focused on increasing adherence to medications for tobacco depen-
dence. The stated aim of the intervention was to evaluate the efficacy of tailored and untailored
materials as supplements to NRT. The specified primary outcome was rate of continuous absti-
nence. Prompts to comply with the medication were 1 of multiple reported elements of the inter-
vention.
Strecher 2005 Intervention not principally focused on increasing adherence to medications for tobacco depen-
dence. Both intervention and control included a focus on medication use.
Swan 2010 Intervention not principally focused on increasing adherence to medications for tobacco depen-
dence. All arms included a focus on medication use.
Tseng 2017 Although study reports described the intervention as an adherence Intervention it was not princi-
pally focused on increasing adherence to medications for tobacco dependence. The intervention
tested was equally split between providing standard smoking cessation advice and material de-
signed to enhance adherence.
Tønnessen 2006   Intervention not principally focused on increasing adherence to medications for tobacco depen-
dence. The stated aim of the intervention was "to evaluate the efficacy of the nicotine sublingual
tablet or placebo combined with either low or high behavioral support for smoking cessation in
COPD [chronic obstructive pulmonary disease] patients after 6 months and 12 months" with speci-
fied primary and secondary outcomes being smoking cessation, smoking reduction and quality of
life. The intervention was described as "counselling on smoking cessation… and subjects were al-
so given take-home material with tips on smoking cessation". Participants were "recommended to
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Study Reason for exclusion
use study medication" as 1 of multiple reported elements of the counselling intervention but it was
not reported that this was administered differentially to intervention and control arms.
Willemsen 2006 No eligible adherence outcome assessed – included a measure of use vs no use of medication.
NRT: nicotine replacement therapy.
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Quote (from abstract): "A secure web program was created to properly dose cigarette smokers to
gum strength (2 vs. 4 mg) and dosing program (# of pieces/day [PPD]). The program then sends
SMS text messaging to the user's cellular telephone to prompt medication use at regular intervals.
We then conducted a randomised trial examining tailored text messaging (TTM) to support text
messaging (STM) in 110 cigarette smokers attempting to quit smoking while using nicotine gum."
Participants The sample was 53% men, 63% white, aged 43 years (SD 11) and smoked 19 (SD 7.6) CPD. There
were no differences between groups at baseline for CPD, gum dosing and recommended pieces per
day.
Interventions Tailored text messaging vs support text messaging
Outcomes Outcome variables included self-reported 7-day recalls of nicotine gum use and cigarette smoking
at 7, 28 and 56 days post quit date.
Notes Requires assessment of full text to confirm eligibility but only an abstract is seemingly available.
Lead author unable to be contacted, although member of author team who was able to be con-
tacted (May 2013) indicated that the study was conducted by a company and had not been writ-
ten up for publication. Abstract presented results as follows: on an intent-to-treat basis, indepen-
dent-sample t-tests revealed that subjects in the tailored text messaging group reported chewing
more nicotine gum than participants in the support text messaging group, (6.5 pieces per day with
tailored text messaging vs 4.5 pieces per day with support text messaging; P = 0.003). No significant




Methods Design: randomised controlled trial
Country: China
Participants Smokers willing to make a quit attempt.
Interventions Intervention group: varenicline combined with a mobile telephone text messaging smoking ces-
sation programme. The programme comprised motivational messages, support for behavioural
change and 'medicine attention'.
Control group: varenicline only
Outcomes Primary outcomes were varenicline usage for 12 weeks and self-reported continuous smoking ab-
stinence, biochemically verified by exhaled carbon monoxide test at 3 and 6 months.
Yuhongxia 2011 
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Notes Only an abstract available. Unclear from this whether the principal focus of the intervention was on
increasing adherence, although this seems unlikely from the abstract content. We were unable to
contact the authors to receive more information.
Yuhongxia 2011  (Continued)
CPD: cigarettes per day.
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Stage Ib Trial of mSMART for Smoking Cessation Medication Adherence (mSMART-Ib)
Methods Parallel RCT. Primary aim to conduct a 60-patient feasibility, acceptability and preliminary efficacy
study of mSMART (Mobile App based Personalized Solutions and Tools for Medication Adherence of
Rx tablet), a smartphone application ('app') for improving medication adherence among substance
users. The investigators will compare 2 groups of cigarette smokers undergoing a quit attempt with
varenicline (Chantix).
Participants 60 participants; aged 18–65 years; recently prescribed varenicline (Chantix) with the intention to
quit smoking in the next 3 months; has an Android smartphone (using v5.x.x or lollipop) or Apple
smartphone (iPhone) Operating System (iOS) (using v6.0).
Interventions Experimental group: using the mSMART app on their smartphone and a MEMS Cap, a smart tablet
box that will a record a date and time-stamped medication event whenever tablet box is opened
and closed, and thus allow for primary measurement of medication adherence).
Control group: using the MEMS Cap and mobile web-based surveys on their smartphone but no
mSMART application.
Outcomes Primary outcomes
• Adherence to smoking cessation medication as assessed via MEMS (time frame: week 12). The
MEMS Cap, placed on the participant's medication bottle, will document the number of times the
bottle is opened per day, totalled at the end of study participation.
• Acceptability of mSMART based on responses to an exit interview (time frame: week 12). Accept-
ability of mSMART will be based on responses to an exit interview at the end of the study (visit 2).
Questionnaire asks for agreement with statements relating to acceptability of the app. Response
options will be quantified on a Likert scale (1 = not at all, 2 = somewhat, 3 = moderately, 4 = ex-
tremely). Example question: what was your overall satisfaction with mSMART?
• Feasibility of mSMART based on frequency of participant use of the app (time frame: week 12).
Feasibility of mSMART will be based on frequency of participant use of the app, totalled at the
end of the study.
Starting date April 2016
Contact information F Joseph McClernon; joseph.mcclernon@duke.edu
Notes Detailed in registration at ClinicalTrials.gov: NCT02635919
NCT02635919 
MEMS: medication event monitoring system; RCT: randomised controlled trial.
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Comparison 1.   Medication adherence intervention plus standard care versus standard care alone





Statistical method Effect size
1 Adherence (combined dichotomous and
continuous)
10 3655 Std. Mean Difference (Random,
95% CI)
0.10 [0.03, 0.18]
2 Adherence: intervention focus subgroups 10 3655 Std. Mean Difference (Random,
95% CI)
0.10 [0.03, 0.18]
2.1 Perceptions 3 839 Std. Mean Difference (Random,
95% CI)
0.10 [-0.03, 0.24]
2.2 Practicalities 5 1752 Std. Mean Difference (Random,
95% CI)
0.21 [0.03, 0.38]
2.3 Both perceptions and practicalities 4 1064 Std. Mean Difference (Random,
95% CI)
0.04 [-0.08, 0.16]
3 Adherence: delivery approach subgroups 10 3655 Std. Mean Difference (Random,
95% CI)
0.10 [0.03, 0.18]
3.1 Participant-centred 8 2791 Std. Mean Difference (Random,
95% CI)
0.12 [0.02, 0.23]
3.2 Clinician-centred 3 864 Std. Mean Difference (Random,
95% CI)
0.09 [-0.05, 0.23]
4 Adherence: combined focus and delivery
subgroups
10 3655 Std. Mean Difference (Random,
95% CI)
0.10 [0.03, 0.18]
4.1 Perceptions + participant 2 206 Std. Mean Difference (Random,
95% CI)
0.03 [-0.25, 0.30]
4.2 Perceptions + clinician 1 633 Std. Mean Difference (Random,
95% CI)
0.13 [-0.03, 0.29]
4.3 Practicalities + participant 5 1752 Std. Mean Difference (Random,
95% CI)
0.21 [0.03, 0.38]
4.4 Both + participant 2 833 Std. Mean Difference (Random,
95% CI)
0.08 [-0.16, 0.32]
4.5 Both + clinician 2 231 Std. Mean Difference (Random,
95% CI)
-0.01 [-0.27, 0.24]
5 Adherence: medication type subgroups 10 3655 Std. Mean Difference (Random,
95% CI)
0.10 [0.03, 0.18]
5.1 Nicotine replacement therapy 7 3442 Std. Mean Difference (Random,
95% CI)
0.09 [0.02, 0.17]
5.2 Bupropion 2 152 Std. Mean Difference (Random,
95% CI)
0.58 [0.14, 1.01]
5.3 Varenicline 1 61 Std. Mean Difference (Random,
95% CI)
-0.22 [-0.73, 0.29]
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Statistical method Effect size
6 Dichotomous adherence data (for calcula-
tion purposes)
6 1664 Odds Ratio (M-H, Random,
95% CI)
1.53 [1.05, 2.21]
7 Continuous adherence data (for calculation
purposes)
5 4604 Std. Mean Difference (IV, Ran-
dom, 95% CI)
0.11 [0.03, 0.19]
8 Short-term smoking abstinence (< 6
months)
5 1795 Risk Ratio (M-H, Random, 95%
CI)
1.08 [0.96, 1.21]





Analysis 1.1.   Comparison 1 Medication adherence intervention plus standard care versus
standard care alone, Outcome 1 Adherence (combined dichotomous and continuous).




Std. Mean Difference Weight Std. Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
Chan 2010 249 252 0 (0.146) 6.79% 0.05[-0.24,0.33]
Chan 2011 479 449 0.1 (0.073) 23.52% 0.09[-0.06,0.23]
Marteau 2012 315 318 0.1 (0.082) 19.43% 0.13[-0.03,0.29]
Mooney 2005 22 14 0.3 (0.344) 1.27% 0.31[-0.37,0.99]
Mooney 2007 27 28 0.5 (0.309) 1.57% 0.54[-0.07,1.14]
Nollen 2011 32 29 -0.2 (0.258) 2.25% -0.22[-0.73,0.29]
Schlam 2018 85 85 -0 (0.153) 6.17% -0.03[-0.33,0.27]
Schlam 2018 85 85 0.1 (0.153) 6.17% 0.06[-0.24,0.36]
Schlam 2018 86 85 0.3 (0.153) 6.17% 0.34[0.04,0.64]
Schmitz 2005 51 46 0.6 (0.318) 1.49% 0.62[-0,1.24]
Smith 2013 413 386 0 (0.071) 24.28% 0.04[-0.1,0.18]
Tucker 2017 18 16 0.5 (0.411) 0.89% 0.48[-0.32,1.29]
   
Total (95% CI)       100% 0.1[0.03,0.18]
Heterogeneity: Tau2=0; Chi2=11.72, df=11(P=0.39); I2=6.13%  
Test for overall effect: Z=2.63(P=0.01)  
Favours control 10.5-1 -0.5 0 Favours intervention
 
 
Analysis 1.2.   Comparison 1 Medication adherence intervention plus standard care
versus standard care alone, Outcome 2 Adherence: intervention focus subgroups.




Std. Mean Difference Weight Std. Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
1.2.1 Perceptions  
Marteau 2012 315 318 0.1 (0.082) 19.43% 0.13[-0.03,0.29]
Mooney 2005 22 14 0.3 (0.344) 1.27% 0.31[-0.37,0.99]
Schlam 2018 85 85 -0 (0.153) 6.17% -0.03[-0.33,0.27]
Favours control 10.5-1 -0.5 0 Favours intervention
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Std. Mean Difference Weight Std. Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
Subtotal (95% CI)       26.87% 0.1[-0.03,0.24]
Heterogeneity: Tau2=0; Chi2=1.23, df=2(P=0.54); I2=0%  
Test for overall effect: Z=1.47(P=0.14)  
   
1.2.2 Practicalities  
Chan 2010 249 252 0 (0.146) 6.79% 0.05[-0.24,0.33]
Chan 2011 479 449 0.1 (0.073) 23.52% 0.09[-0.06,0.23]
Mooney 2007 27 28 0.5 (0.309) 1.57% 0.54[-0.07,1.14]
Schlam 2018 86 85 0.3 (0.153) 6.17% 0.34[0.04,0.64]
Schmitz 2005 51 46 0.6 (0.318) 1.49% 0.62[-0,1.24]
Subtotal (95% CI)       39.54% 0.21[0.03,0.38]
Heterogeneity: Tau2=0.02; Chi2=6.56, df=4(P=0.16); I2=38.99%  
Test for overall effect: Z=2.24(P=0.03)  
   
1.2.3 Both perceptions and practicalities  
Nollen 2011 32 29 -0.2 (0.258) 2.25% -0.22[-0.73,0.29]
Schlam 2018 85 85 0.1 (0.153) 6.17% 0.06[-0.24,0.36]
Smith 2013 413 386 0 (0.071) 24.28% 0.04[-0.1,0.18]
Tucker 2017 18 16 0.5 (0.411) 0.89% 0.48[-0.32,1.29]
Subtotal (95% CI)       33.59% 0.04[-0.08,0.16]
Heterogeneity: Tau2=0; Chi2=2.2, df=3(P=0.53); I2=0%  
Test for overall effect: Z=0.62(P=0.54)  
   
Total (95% CI)       100% 0.1[0.03,0.18]
Heterogeneity: Tau2=0; Chi2=11.72, df=11(P=0.39); I2=6.13%  
Test for overall effect: Z=2.63(P=0.01)  
Test for subgroup differences: Chi2=2.29, df=1 (P=0.32), I2=12.79%  
Favours control 10.5-1 -0.5 0 Favours intervention
 
 
Analysis 1.3.   Comparison 1 Medication adherence intervention plus standard care
versus standard care alone, Outcome 3 Adherence: delivery approach subgroups.




Std. Mean Difference Weight Std. Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
1.3.1 Participant-centred  
Chan 2010 249 252 0 (0.146) 6.79% 0.05[-0.24,0.33]
Chan 2011 479 449 0.1 (0.073) 23.52% 0.09[-0.06,0.23]
Mooney 2005 22 14 0.3 (0.344) 1.27% 0.31[-0.37,0.99]
Mooney 2007 27 28 0.5 (0.309) 1.57% 0.54[-0.07,1.14]
Schlam 2018 85 85 -0 (0.153) 6.17% -0.03[-0.33,0.27]
Schlam 2018 86 85 0.3 (0.153) 6.17% 0.34[0.04,0.64]
Schmitz 2005 51 46 0.6 (0.318) 1.49% 0.62[-0,1.24]
Smith 2013 413 386 0 (0.071) 24.28% 0.04[-0.1,0.18]
Tucker 2017 18 16 0.5 (0.411) 0.89% 0.48[-0.32,1.29]
Subtotal (95% CI)       72.15% 0.12[0.02,0.23]
Heterogeneity: Tau2=0; Chi2=9.97, df=8(P=0.27); I2=19.74%  
Test for overall effect: Z=2.26(P=0.02)  
   
Favours control 10.5-1 -0.5 0 Favours intervention
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Std. Mean Difference Weight Std. Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
1.3.2 Clinician-centred  
Marteau 2012 315 318 0.1 (0.082) 19.43% 0.13[-0.03,0.29]
Nollen 2011 32 29 -0.2 (0.258) 2.25% -0.22[-0.73,0.29]
Schlam 2018 85 85 0.1 (0.153) 6.17% 0.06[-0.24,0.36]
Subtotal (95% CI)       27.85% 0.09[-0.05,0.23]
Heterogeneity: Tau2=0; Chi2=1.73, df=2(P=0.42); I2=0%  
Test for overall effect: Z=1.3(P=0.19)  
   
Total (95% CI)       100% 0.1[0.03,0.18]
Heterogeneity: Tau2=0; Chi2=11.72, df=11(P=0.39); I2=6.13%  
Test for overall effect: Z=2.63(P=0.01)  
Test for subgroup differences: Chi2=0.13, df=1 (P=0.71), I2=0%  
Favours control 10.5-1 -0.5 0 Favours intervention
 
 
Analysis 1.4.   Comparison 1 Medication adherence intervention plus standard care versus
standard care alone, Outcome 4 Adherence: combined focus and delivery subgroups.




Std. Mean Difference Weight Std. Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
1.4.1 Perceptions + participant  
Mooney 2005 22 14 0.3 (0.344) 1.27% 0.31[-0.37,0.99]
Schlam 2018 85 85 -0 (0.153) 6.17% -0.03[-0.33,0.27]
Subtotal (95% CI)       7.44% 0.03[-0.25,0.3]
Heterogeneity: Tau2=0; Chi2=0.81, df=1(P=0.37); I2=0%  
Test for overall effect: Z=0.19(P=0.85)  
   
1.4.2 Perceptions + clinician  
Marteau 2012 315 318 0.1 (0.082) 19.43% 0.13[-0.03,0.29]
Subtotal (95% CI)       19.43% 0.13[-0.03,0.29]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.59(P=0.11)  
   
1.4.3 Practicalities + participant  
Chan 2010 249 252 0 (0.146) 6.79% 0.05[-0.24,0.33]
Chan 2011 479 449 0.1 (0.073) 23.52% 0.09[-0.06,0.23]
Mooney 2007 27 28 0.5 (0.309) 1.57% 0.54[-0.07,1.14]
Schlam 2018 86 85 0.3 (0.153) 6.17% 0.34[0.04,0.64]
Schmitz 2005 51 46 0.6 (0.318) 1.49% 0.62[-0,1.24]
Subtotal (95% CI)       39.54% 0.21[0.03,0.38]
Heterogeneity: Tau2=0.02; Chi2=6.56, df=4(P=0.16); I2=38.99%  
Test for overall effect: Z=2.24(P=0.03)  
   
1.4.4 Both + participant  
Smith 2013 413 386 0 (0.071) 24.28% 0.04[-0.1,0.18]
Tucker 2017 18 16 0.5 (0.411) 0.89% 0.48[-0.32,1.29]
Subtotal (95% CI)       25.17% 0.08[-0.16,0.32]
Heterogeneity: Tau2=0.01; Chi2=1.13, df=1(P=0.29); I2=11.37%  
Test for overall effect: Z=0.63(P=0.53)  
Favours control 10.5-1 -0.5 0 Favours intervention
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Std. Mean Difference Weight Std. Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
   
1.4.5 Both + clinician  
Nollen 2011 32 29 -0.2 (0.258) 2.25% -0.22[-0.73,0.29]
Schlam 2018 85 85 0.1 (0.153) 6.17% 0.06[-0.24,0.36]
Subtotal (95% CI)       8.42% -0.01[-0.27,0.24]
Heterogeneity: Tau2=0; Chi2=0.87, df=1(P=0.35); I2=0%  
Test for overall effect: Z=0.1(P=0.92)  
   
Total (95% CI)       100% 0.1[0.03,0.18]
Heterogeneity: Tau2=0; Chi2=11.72, df=11(P=0.39); I2=6.13%  
Test for overall effect: Z=2.63(P=0.01)  
Test for subgroup differences: Chi2=2.44, df=1 (P=0.65), I2=0%  
Favours control 10.5-1 -0.5 0 Favours intervention
 
 
Analysis 1.5.   Comparison 1 Medication adherence intervention plus standard care
versus standard care alone, Outcome 5 Adherence: medication type subgroups.




Std. Mean Difference Weight Std. Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
1.5.1 Nicotine replacement therapy  
Chan 2010 249 252 0 (0.146) 6.79% 0.05[-0.24,0.33]
Chan 2011 479 449 0.1 (0.073) 23.52% 0.09[-0.06,0.23]
Marteau 2012 315 318 0.1 (0.082) 19.43% 0.13[-0.03,0.29]
Mooney 2005 22 14 0.3 (0.344) 1.27% 0.31[-0.37,0.99]
Schlam 2018 85 85 -0 (0.153) 6.17% -0.03[-0.33,0.27]
Schlam 2018 85 85 0.1 (0.153) 6.17% 0.06[-0.24,0.36]
Schlam 2018 86 85 0.3 (0.153) 6.17% 0.34[0.04,0.64]
Smith 2013 413 386 0 (0.071) 24.28% 0.04[-0.1,0.18]
Tucker 2017 18 16 0.5 (0.411) 0.89% 0.48[-0.32,1.29]
Subtotal (95% CI)       94.69% 0.09[0.02,0.17]
Heterogeneity: Tau2=0; Chi2=5.45, df=8(P=0.71); I2=0%  
Test for overall effect: Z=2.5(P=0.01)  
   
1.5.2 Bupropion  
Mooney 2007 27 28 0.5 (0.309) 1.57% 0.54[-0.07,1.14]
Schmitz 2005 51 46 0.6 (0.318) 1.49% 0.62[-0,1.24]
Subtotal (95% CI)       3.06% 0.58[0.14,1.01]
Heterogeneity: Tau2=0; Chi2=0.04, df=1(P=0.84); I2=0%  
Test for overall effect: Z=2.61(P=0.01)  
   
1.5.3 Varenicline  
Nollen 2011 32 29 -0.2 (0.258) 2.25% -0.22[-0.73,0.29]
Subtotal (95% CI)       2.25% -0.22[-0.73,0.29]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.85(P=0.39)  
   
Total (95% CI)       100% 0.1[0.03,0.18]
Heterogeneity: Tau2=0; Chi2=11.72, df=11(P=0.39); I2=6.13%  
Favours control 10.5-1 -0.5 0 Favours intervention
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Std. Mean Difference Weight Std. Mean Difference
  N N (SE) IV, Random, 95% CI   IV, Random, 95% CI
Test for overall effect: Z=2.63(P=0.01)  
Test for subgroup differences: Chi2=6.23, df=1 (P=0.04), I2=67.87%  
Favours control 10.5-1 -0.5 0 Favours intervention
 
 
Analysis 1.6.   Comparison 1 Medication adherence intervention plus standard care versus
standard care alone, Outcome 6 Dichotomous adherence data (for calculation purposes).
Study or subgroup Intervention Control Odds Ratio Weight Odds Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Chan 2010 34/249 32/252 25.33% 1.09[0.65,1.83]
Chan 2011 270/479 236/449 40.45% 1.17[0.9,1.51]
Mooney 2005 7/27 3/22 5.48% 2.22[0.5,9.85]
Mooney 2007 15/27 9/28 9.25% 2.64[0.88,7.91]
Schmitz 2005 28/51 13/46 13.84% 3.09[1.33,7.2]
Tucker 2017 8/18 4/16 5.65% 2.4[0.55,10.38]
   
Total (95% CI) 851 813 100% 1.53[1.05,2.21]
Total events: 362 (Intervention), 297 (Control)  
Heterogeneity: Tau2=0.07; Chi2=7.92, df=5(P=0.16); I2=36.89%  
Test for overall effect: Z=2.24(P=0.03)  
Favours control 1000.01 100.1 1 Favours intervention
 
 
Analysis 1.7.   Comparison 1 Medication adherence intervention plus standard care versus
standard care alone, Outcome 7 Continuous adherence data (for calculation purposes).
Study or subgroup Intervention Control Std. Mean Difference Weight Std. Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Marteau 2012 315 68.5 (36.3) 318 63.6 (39) 11.54% 0.13[-0.03,0.29]
Mooney 2005 22 120.1 (55.3) 14 102.5 (53.9) 1.36% 0.31[-0.36,0.99]
Nollen 2011 32 82.1 (36.4) 29 89.2 (24.4) 2.3% -0.22[-0.73,0.28]
Schlam 2018 85 28.3 (32.5) 85 29.3 (32.7) 5.36% -0.03[-0.33,0.27]
Schlam 2018 85 29.8 (33.1) 85 27.8 (32.1) 5.36% 0.06[-0.24,0.36]
Schlam 2018 86 34.3 (35.9) 85 23.3 (27.8) 5.33% 0.34[0.04,0.64]
Schlam 2018 257 28.3 (32.5) 256 29.3 (32.7) 10.51% -0.03[-0.2,0.14]
Schlam 2018 258 34.3 (35.9) 255 23.3 (27.8) 10.43% 0.34[0.17,0.52]
Schlam 2018 256 29.8 (33.1) 257 27.8 (32.1) 10.5% 0.06[-0.11,0.24]
Schlam 2018 128 28.3 (32.5) 128 29.3 (32.7) 7.11% -0.03[-0.27,0.22]
Schlam 2018 129 34.3 (35.9) 127 23.3 (27.8) 7.04% 0.34[0.09,0.59]
Schlam 2018 256 29.8 (33.1) 257 27.8 (32.1) 10.5% 0.06[-0.11,0.24]
Smith 2013 413 10 (5.1) 386 9.8 (4.9) 12.66% 0.04[-0.1,0.18]
   
Total *** 2322   2282   100% 0.11[0.03,0.19]
Heterogeneity: Tau2=0.01; Chi2=20.76, df=12(P=0.05); I2=42.21%  
Test for overall effect: Z=2.57(P=0.01)  
Favours control 10.5-1 -0.5 0 Favours intervention
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Analysis 1.8.   Comparison 1 Medication adherence intervention plus standard care
versus standard care alone, Outcome 8 Short-term smoking abstinence (< 6 months).
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Marteau 2012 151/315 147/318 51.08% 1.04[0.88,1.22]
Mooney 2005 13/32 10/31 3.2% 1.26[0.65,2.44]
Nollen 2011 8/36 9/36 2.01% 0.89[0.39,2.04]
Smith 2013 172/502 150/485 43.07% 1.11[0.93,1.33]
Tucker 2017 6/20 2/20 0.64% 3[0.69,13.12]
   
Total (95% CI) 905 890 100% 1.08[0.96,1.21]
Total events: 350 (Intervention), 318 (Control)  
Heterogeneity: Tau2=0; Chi2=2.58, df=4(P=0.63); I2=0%  
Test for overall effect: Z=1.24(P=0.21)  
Favours control 100.1 50.2 20.5 1 Favours intervention
 
 
Analysis 1.9.   Comparison 1 Medication adherence intervention plus standard care
versus standard care alone, Outcome 9 Long-term smoking abstinence (≥ 6 months).
Study or subgroup Intervention Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Chan 2010 33/249 24/252 9.87% 1.39[0.85,2.28]
Chan 2011 48/479 26/449 10.93% 1.73[1.09,2.74]
Marteau 2012 43/315 25/318 10.68% 1.74[1.09,2.77]
Schlam 2018 34/90 36/91 14.36% 0.95[0.66,1.38]
Schlam 2018 36/91 33/91 14.13% 1.09[0.75,1.58]
Schlam 2018 34/90 35/91 14.18% 0.98[0.68,1.42]
Smith 2013 184/502 182/485 25.85% 0.98[0.83,1.15]
   
Total (95% CI) 1816 1777 100% 1.16[0.96,1.4]
Total events: 412 (Intervention), 361 (Control)  
Heterogeneity: Tau2=0.03; Chi2=11.51, df=6(P=0.07); I2=47.85%  
Test for overall effect: Z=1.56(P=0.12)  
Favours control 20.5 1.50.7 1 Favours intervention
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Study Brief description of specific intervention components in-




























Table 1.   Brief descriptions of adherence interventions 
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Chan 2010 Added counselling contact time to standard behavioural sup-





Chan 2011 Added counselling contact time to standard behavioural sup-







Tailored and communicated about NRT dosage using a more
























Added counselling contact time to standard behavioural sup-






Added contact time to standard behavioural support with: 1.
medication adherence counselling; 2. automated reminder
calls; 3. electronic monitoring counselling























Added counselling contact time to standard behavioural sup-
port, focusing specifically on medication adherence




Added contact time to standard behavioural support with mod-
ule focused on improving adherence to nicotine patch
Yes NRT Both Partici-
pant
Table 1.   Brief descriptions of adherence interventions  (Continued)
aFor further details see Characteristics of included studies table.
NRT: nicotine replacement therapy.
 
 
A P P E N D I C E S
Appendix 1. Cochrane Tobacco Addiction Groups Specialized Register search strategy
1. (adhere* or complian* or concord* or discontinu*):TI,AB,MH,EMT,KY,KW,XKY
2. Medication Adherence:MH,EMT,KY,KW,XKY
3. ((NRT or nicotine replacement therap* or bupropion or wellbutrin or zyban or voxra or budeprion or aplenzin or amfebutamone or
varenicline or chantix or champix) OR (nicotine adj7 (patch* or gum* or inhaler* or inhalator* or lozenge* or microtab* or tablet* or
spray*))):TI,AB,MH,EMT,KY,KW,XKY
4. #1 OR #2
5. #3 AND #4
Appendix 2. Taxonomy of possible interventions (adapted from Haynes 2008)
• More instruction for patients, e.g. verbal, written or visual material; programmed learning and formal education sessions;
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• counselling about the patients' target condition, the importance of therapy and compliance with therapy, the possible adverse effects,
patient empowerment, couple-focused therapy to increase social support;
• automated telephone, computer-assisted patient monitoring and counselling;
• manual telephone follow-up;
• family intervention;
• various ways to increase the convenience of care, e.g. provision at the work site or at home;
• simplified dosing;
• involving patients more in their care through self-monitoring;
• reminders, e.g. programmed devices, and tailoring the regimen to daily habits;
• special 'reminder' medication packaging;
• dose-dispensing units of medication and medication charts;
• appointment and prescription refill reminders;
• reinforcement or rewards for both improved adherence and treatment response, e.g. reduced frequency of visits;
• different medication formulations, such as tablet versus syrup;
• crisis intervention conducted when necessary;
• direct observation of treatments (DOTS) by health workers or family members;
• lay health mentoring;
• augmented pharmacy services;
• psychological therapy, e.g. cognitive behaviour therapy, multisystemic therapy;
• mailed communications;
• group meetings.
W H A T ' S   N E W
 
Date Event Description
18 July 2019 New search has been performed Updated searches: two new studies
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
For the 2015 version of the review (Hollands 2015b), the criteria for eligible interventions was refined between the protocol and the review.
The original primary intention of the review was to examine the effect of interventions to increase adherence where this was the clearly
intended focus of those intervening. However, this primary intention was not adequately reflected in the original criteria. As such, a large
number of studies of interventions that could in theory alter adherence but where this was not the researchers' intention would have been
relevant for inclusion. Furthermore, this lack of clarity meant that most extant studies that featured any intervention in smokers would
have to be examined at the full-text screening stage because a clear focus on increasing adherence (which can typically be derived from
the title and abstract screening process) was not necessary for consideration for inclusion.
For the current update, we made additional changes to the original protocol.
Rather than including separate meta-analyses combining each of continuous outcome data and dichotomous outcome data for a given
outcome, we produced a single meta-analysis that combined these using generic inverse variance methods. If a study reported both con-
tinuous and dichotomous outcomes that were similar in meeting other criteria, continuous data were used. In the previous version of
the review, we had applied fixed-effect models to our pooling of the data. This was in line with the protocol, in which we stated that we
intended to group substantially similar studies. In practice, there was considerable methodological and clinical variance between stud-
ies, reflecting different characteristics of settings, participant groups, interventions and measures. As such, a random-effects model was
considered more appropriate.
We added formal coding of the focus of the content of the intervention, which while stated as an objective, had not been conducted for
the previous version of this review. We coded studies by reference to two key factors: 1. focus on perceptions, practicalities, or both; 2.
participant-centred or clinician-centred. This was then used as the basis for subgroup analyses to determine which types of interventions
were most effective.
In the previous version of this review we proposed to assess the impact of using intention-to-treat data for adherence outcomes instead
of using data for only those participants who remained engaged with treatment (the latter being our specified preferred approach). This
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was no longer considered necessary given justification for using the latter data, reflected in the two newly identified studies which both
report adherence data for participants who remained engaged with treatment.
For risk of bias assessment, following guidance from the Cochrane Tobacco Addiction Group, we removed three domains (blinding of par-
ticipants and personnel (performance bias); validity and reliability of outcome measures (other sources of bias); comparability of baseline
characteristics (other sources of bias)). We followed guidance in Section 8.7 (Table 8.7a) of the Cochrane Handbook for Systematic Reviews
of Interventions for deriving a summary risk of bias judgement from the domains that were assessed (Higgins 2011).
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Benzazepines  [therapeutic use];  Bupropion  [therapeutic use];  Drug Therapy, Combination  [methods];  Medication Adherence  [*statistics
& numerical data];  Nicotinic Agonists  [*therapeutic use];  Nortriptyline  [therapeutic use];  Quinoxalines  [therapeutic use];  Randomized
Controlled Trials as Topic;  Smoking Cessation  [*methods];  Tobacco Use Disorder  [*drug therapy];  Varenicline
MeSH check words
Humans
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